49 results
Search Results
2. The Tuberculosis Cascade of Care in India's Public Sector: A Systematic Review and Meta-analysis.
- Author
-
Subbaraman, Ramnath, Nathavitharana, Ruvandhi R., Satyanarayana, Srinath, Pai, Madhukar, Thomas, Beena E., Chadha, Vineet K., Rade, Kiran, Swaminathan, Soumya, and Mayer, Kenneth H.
- Subjects
PUBLIC sector ,TUBERCULOSIS ,TUBERCULOSIS hospitals ,TUBERCULOSIS prevention ,TUBERCULOSIS treatment - Abstract
Background: India has 23% of the global burden of active tuberculosis (TB) patients and 27% of the world's "missing" patients, which includes those who may not have received effective TB care and could potentially spread TB to others. The "cascade of care" is a useful model for visualizing deficiencies in case detection and retention in care, in order to prioritize interventions.Methods and Findings: The care cascade constructed in this paper focuses on the Revised National TB Control Programme (RNTCP), which treats about half of India's TB patients. We define the TB cascade as including the following patient populations: total prevalent active TB patients in India, TB patients who reach and undergo evaluation at RNTCP diagnostic facilities, patients successfully diagnosed with TB, patients who start treatment, patients retained to treatment completion, and patients who achieve 1-y recurrence-free survival. We estimate each step of the cascade for 2013 using data from two World Health Organization (WHO) reports (2014-2015), one WHO dataset (2015), and three RNTCP reports (2014-2016). In addition, we conduct three targeted systematic reviews of the scientific literature to identify 39 unique articles published from 2000-2015 that provide additional data on five indicators that help estimate different steps of the TB cascade. We construct separate care cascades for the overall population of patients with active TB and for patients with specific forms of TB-including new smear-positive, new smear-negative, retreatment smear-positive, and multidrug-resistant (MDR) TB. The WHO estimated that there were 2,700,000 (95%CI: 1,800,000-3,800,000) prevalent TB patients in India in 2013. Of these patients, we estimate that 1,938,027 (72%) TB patients were evaluated at RNTCP facilities; 1,629,906 (60%) were successfully diagnosed; 1,417,838 (53%) got registered for treatment; 1,221,764 (45%) completed treatment; and 1,049,237 (95%CI: 1,008,775-1,083,243), or 39%, of 2,700,000 TB patients achieved the optimal outcome of 1-y recurrence-free survival. The separate cascades for different forms of TB highlight different patterns of patient attrition. Pretreatment loss to follow-up of diagnosed patients and post-treatment TB recurrence were major points of attrition in the new smear-positive TB cascade. In the new smear-negative and MDR TB cascades, a substantial proportion of patients who were evaluated at RNTCP diagnostic facilities were not successfully diagnosed. Retreatment smear-positive and MDR TB patients had poorer treatment outcomes than the general TB population. Limitations of our analysis include the lack of available data on the cascade of care in the private sector and substantial uncertainty regarding the 1-y period prevalence of TB in India.Conclusions: Increasing case detection is critical to improving outcomes in India's TB cascade of care, especially for smear-negative and MDR TB patients. For new smear-positive patients, pretreatment loss to follow-up and post-treatment TB recurrence are considerable points of attrition that may contribute to ongoing TB transmission. Future multisite studies providing more accurate information on key steps in the public sector TB cascade and extension of this analysis to private sector patients may help to better target interventions and resources for TB control in India. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
3. Prevalence and characteristics of long COVID in elderly patients: An observational cohort study of over 2 million adults in the US.
- Author
-
Fung, Kin Wah, Baye, Fitsum, Baik, Seo H., Zheng, Zhaonian, and McDonald, Clement J.
- Subjects
POST-acute COVID-19 syndrome ,OLDER patients ,COVID-19 ,MEDICARE ,BACTERIAL diseases ,VIRUS diseases ,MEDICAID ,TASTE disorders ,SMELL disorders - Abstract
Background: Incidence of long COVID in the elderly is difficult to estimate and can be underreported. While long COVID is sometimes considered a novel disease, many viral or bacterial infections have been known to cause prolonged illnesses. We postulate that some influenza patients might develop residual symptoms that would satisfy the diagnostic criteria for long COVID, a condition we call "long Flu." In this study, we estimate the incidence of long COVID and long Flu among Medicare patients using the World Health Organization (WHO) consensus definition. We compare the incidence, symptomatology, and healthcare utilization between long COVID and long Flu patients. Methods and findings: This is a cohort study of Medicare (the US federal health insurance program) beneficiaries over 65. ICD-10-CM codes were used to capture COVID-19, influenza, and residual symptoms. Long COVID was identified by (a) the designated long COVID code B94.8 (code-based definition), or (b) any of 11 symptoms identified in the WHO definition (symptom-based definition), from 1 to 3 months post-infection. A symptom would be excluded if it occurred in the year prior to infection. Long Flu was identified in influenza patients from the combined 2018 and 2019 Flu seasons by the same symptom-based definition for long COVID. Long COVID and long Flu were compared in 4 outcome measures: (a) hospitalization (any cause); (b) hospitalization (for long COVID symptom); (c) emergency department (ED) visit (for long COVID symptom); and (d) number of outpatient encounters (for long COVID symptom), adjusted for age, sex, race, region, Medicare-Medicaid dual eligibility status, prior-year hospitalization, and chronic comorbidities. Among 2,071,532 COVID-19 patients diagnosed between April 2020 and June 2021, symptom-based definition identified long COVID in 16.6% (246,154/1,479,183) and 29.2% (61,631/210,765) of outpatients and inpatients, respectively. The designated code gave much lower estimates (outpatients 0.49% (7,213/1,479,183), inpatients 2.6% (5,521/210,765)). Among 933,877 influenza patients, 17.0% (138,951/817,336) of outpatients and 24.6% (18,824/76,390) of inpatients fit the long Flu definition. Long COVID patients had higher incidence of dyspnea, fatigue, palpitations, loss of taste/smell, and neurocognitive symptoms compared to long Flu. Long COVID outpatients were more likely to have any-cause hospitalization (31.9% (74,854/234,688) versus 26.8% (33,140/123,736), odds ratio 1.06 (95% CI 1.05 to 1.08, p < 0.001)), and more outpatient visits than long Flu outpatients (mean 2.9(SD 3.4) versus 2.5(SD 2.7) visits, incidence rate ratio 1.09 (95% CI 1.08 to 1.10, p < 0.001)). There were less ED visits in long COVID patients, probably because of reduction in ED usage during the pandemic. The main limitation of our study is that the diagnosis of long COVID in is not independently verified. Conclusions: Relying on specific long COVID diagnostic codes results in significant underreporting. We observed that about 30% of hospitalized COVID-19 patients developed long COVID. In a similar proportion of patients, long COVID-like symptoms (long Flu) can be observed after influenza, but there are notable differences in symptomatology between long COVID and long Flu. The impact of long COVID on healthcare utilization is higher than long Flu. In a cohort study from the US including more than 2 million Medicare beneficiaries over the age of 65, Kin Wah Fung and colleagues explore the prevalence and characteristics of long COVID. Author summary: Why was this study done?: The quoted incidence of long COVID varies widely because of differences in definition and measurement method. Long COVID in the elderly is likely to be underreported because they are less likely to respond to surveys, and symptoms may be confused with other chronic diseases. Lingering ill health after infections is not limited to COVID-19. We postulate that some patients may fit the diagnostic criteria of long COVID after a bout of influenza. We call this condition "long Flu." Comparing and contrasting long COVID and long Flu may shed light on the understanding of long COVID, a disease still shrouded in mystery. What did the researchers do and find?: We used the World Health Organization long COVID definition on 2 million Medicare patients with COVID-19 between April 2020 and June 2021. We applied the same definition to almost 900,000 influenza patients during the 2018 and 2019 Flu seasons to identify long Flu. Long COVID occurred in 16.6% of outpatients and 29.2% of inpatients. The corresponding rates for long Flu were 17% and 24.6%. Using only the designated long COVID code, the estimated rates would be 0.5% and 2.6%, way below the reported rates in most studies. Despite the similar overall incidence rates, long COVID patients suffered with notably different symptoms compared to long Flu patients and were also more likely to access inpatient and outpatient healthcare services. What do these findings mean?: The use of designated long COVID diagnostic codes alone is likely to result in gross underreporting of long COVID in this population. Long COVID is associated with greater healthcare utilization than long Flu, suggesting a bigger impact on individual health and well-being, as well as on healthcare expenditure. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial.
- Author
-
Browne, Sara H., Umlauf, Anya, Tucker, Amanda J., Low, Julie, Moser, Kathleen, Gonzalez Garcia, Jonathan, Peloquin, Charles A., Blaschke, Terrence, Vaida, Florin, and Benson, Constance A.
- Subjects
DIRECTLY observed therapy ,RANDOMIZED controlled trials ,TUBERCULOSIS ,MYCOBACTERIUM tuberculosis ,PATIENT compliance ,MULTIDRUG-resistant tuberculosis ,MIDDLE-income countries - Abstract
Background: Excellent adherence to tuberculosis (TB) treatment is critical to cure TB and avoid the emergence of resistance. Wirelessly observed therapy (WOT) is a novel patient self-management system consisting of an edible ingestion sensor (IS), external wearable patch, and paired mobile device that can detect and digitally record medication ingestions. Our study determined the accuracy of ingestion detection in clinical and home settings using WOT and subsequently compared, in a randomized control trial (RCT), confirmed daily adherence to medication in persons using WOT or directly observed therapy (DOT) during TB treatment.Methods and Findings: We evaluated WOT in persons with active Mycobacterium tuberculosis complex disease using IS-enabled combination isoniazid 150 mg/rifampin 300 mg (IS-Rifamate). Seventy-seven participants with drug-susceptible TB in the continuation phase of treatment, prescribed daily isoniazid 300 mg and rifampin 600 mg, used IS-Rifamate. The primary endpoints of the trial were determination of the positive detection accuracy (PDA) of WOT, defined as the percentage of ingestions detected by WOT administered under direct observation, and subsequently the proportion of prescribed doses confirmed by WOT compared to DOT. Initially participants received DOT and WOT simultaneously for 2-3 weeks to allow calculation of WOT PDA, and the 95% confidence interval (CI) was estimated using the bootstrap method with 10,000 samples. Sixty-one participants subsequently participated in an RCT to compare the proportion of prescribed doses confirmed by WOT and DOT. Participants were randomized 2:1 to receive WOT or maximal in-person DOT. In the WOT arm, if ingestions were not remotely confirmed, the participant was contacted within 24 hours by text or cell phone to provide support. The number of doses confirmed was collected, and nonparametric methods were used for group and individual comparisons to estimate the proportions of confirmed doses in each randomized arm with 95% CIs. Sensitivity analyses, not prespecified in the trial registration, were also performed, removing all nonworking (weekend and public holiday) and held-dose days. Participants, recruited from San Diego (SD) and Orange County (OC) Divisions of TB Control and Refugee Health, were 43.1 (range 18-80) years old, 57% male, 42% Asian, and 39% white with 49% Hispanic ethnicity. The PDA of WOT was 99.3% (CI 98.1; 100). Intent-to-treat (ITT) analysis within the RCT showed WOT confirmed 93% versus 63% DOT (p < 0.001) of daily doses prescribed. Secondary analysis removing all nonworking days (weekends and public holidays) and held doses from each arm showed WOT confirmed 95.6% versus 92.7% (p = 0.31); WOT was non-inferior to DOT (difference 2.8% CI [-1.8%, 9.1%]). One hundred percent of participants preferred using WOT. WOT associated adverse events were <10%, consisting of minor skin rash and pruritus associated with the patch. WOT provided longitudinal digital reporting in near real time, supporting patient self-management and allowing rapid remote identification of those who needed more support to maintain adherence. This study was conducted during the continuation phase of TB treatment, limiting its generalizability to the entire TB treatment course.Conclusions: In terms of accuracy, WOT was equivalent to DOT. WOT was superior to DOT in supporting confirmed daily adherence to TB medications during the continuation phase of TB treatment and was overwhelmingly preferred by participants. WOT should be tested in high-burden TB settings, where it may substantially support low- and middle-income country (LMIC) TB programs.Trial Registration: ClinicalTrials.gov NCT01960257. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
5. Simplified clinical algorithm for identifying patients eligible for same-day HIV treatment initiation (SLATE): Results from an individually randomized trial in South Africa and Kenya.
- Author
-
Rosen, Sydney, Maskew, Mhairi, Larson, Bruce A., Brennan, Alana T., Tsikhutsu, Isaac, Fox, Matthew P., Vezi, Lungisile, Bii, Margaret, and Venter, Willem D. F.
- Subjects
MEDICAL protocols ,MEDICAL history taking ,VIRAL load ,HIV ,HIV-positive persons - Abstract
Background: The World Health Organization recommends "same-day" initiation of antiretroviral therapy (ART) for HIV patients who are eligible and ready. Identifying efficient, safe, and feasible procedures for determining same-day eligibility and readiness is now a priority. The Simplified Algorithm for Treatment Eligibility (SLATE) study evaluated a clinical algorithm that allows healthcare workers to determine eligibility for same-day treatment and to initiate ART at the patient's first clinic visit.Methods and Findings: SLATE was an individually randomized trial at three outpatient clinics in urban settlements in Johannesburg, South Africa and three hospital clinics in western Kenya. Adult, nonpregnant, HIV-positive, ambulatory patients presenting for any HIV care, including HIV testing, but not yet on ART were enrolled and randomized to the SLATE algorithm arm or standard care. The SLATE algorithm used four screening tools-a symptom self-report, medical history questionnaire, physical examination, and readiness assessment-to ascertain eligibility for same-day initiation or refer for further care. Follow-up was by record review, and analysis was conducted by country. We report primary outcomes of 1) ART initiation ≤28 days and 2) initiation ≤28 days and retention in care ≤8 months of enrollment. From March 7, 2017 to April 17, 2018, we enrolled 600 patients (median [IQR] age 34 [29-40] and CD4 count 286 [128-490]; 63% female) in South Africa and 477 patients in Kenya (median [IQR] age 35 [29-43] and CD4 count 283 [117-541]; 58% female). In the intervention arm, 78% of patients initiated ≤28 days in South Africa, compared to 68% in the standard arm (risk difference [RD] [95% confidence interval (CI)] 10% [3%-17%]); in Kenya, 94% of intervention-arm patients initiated ≤28 days compared to 89% in the standard arm (6% [0.5%-11%]). By 8 months in South Africa, 161/298 (54%) intervention-arm patients had initiated and were retained, compared to 146/302 (48%) in the standard arm (6% [(2% to 14%]). By 8 months in Kenya, the corresponding retention outcomes were identical in both arms (137/240 [57%] of intervention-arm patients and 136/237 [57%] of standard-arm patients). Limitations of the trial included limited geographic representativeness, exclusion of patients too ill to participate, missing viral load data, greater study fidelity to the algorithm than might be achieved in standard care, and secular changes in standard care over the course of the study.Conclusions: In South Africa, the SLATE algorithm increased uptake of ART within 28 days by 10% and showed a numerical increase (6%) in retention at 8 months. In Kenya, the algorithm increased uptake of ART within 28 days by 6% but found no difference in retention at 8 months. Eight-month retention was poor in both arms and both countries. These results suggest that a simple structured algorithm for same-day treatment initiation procedures is feasible and can increase and accelerate ART uptake but that early retention on treatment remains problematic.Trial Registration: Clinicaltrials.gov NCT02891135, registered September 1, 2016. First participant enrolled March 6, 2017 in South Africa and July 13, 2017 in Kenya. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.
- Author
-
Lienhardt, Christian, Vernon, Andrew A., Cavaleri, Marco, Nambiar, Sumati, and Nahid, Payam
- Subjects
PUBLIC health ,HEALTH policy ,BACTERIAL diseases ,SCIENCE & state ,COMMUNICABLE diseases - Abstract
Christian Lienhardt and colleagues discuss the importance of communication and coordination between regulators, researchers, and policy makers to ensure tuberculosis trials provide high-quality evidence for policy decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons.
- Author
-
Gupta, Amita, Hughes, Michael D., Garcia-Prats, Anthony J., McIntire, Katherine, and Hesseling, Anneke C.
- Subjects
PREGNANT women ,HIV-positive persons ,CLINICAL trials ,CHILDREN ,NEW trials - Abstract
Amita Gupta and colleagues discuss priorities in clinical research aimed at improving tuberculosis prevention and treatment in pregnant women, children, and people with HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Adherence clubs and decentralized medication delivery to support patient retention and sustained viral suppression in care: Results from a cluster-randomized evaluation of differentiated ART delivery models in South Africa.
- Author
-
Fox, Matthew P., Pascoe, Sophie, Huber, Amy N., Murphy, Joshua, Phokojoe, Mokgadi, Gorgens, Marelize, Rosen, Sydney, Wilson, David, Pillay, Yogan, and Fraser-Hurt, Nicole
- Subjects
HEALTH facilities ,CLINICAL trial registries ,PATIENT compliance ,GENERALIZED estimating equations ,VIRAL load - Abstract
Background: Differentiated antiretroviral therapy (ART) delivery models, in which patients are provided with care relevant to their current status (e.g., newly initiating, stable on treatment, or unstable on treatment) has become an essential part of patient-centered health systems. In 2015, the South African government implemented Chronic Disease Adherence Guidelines (AGLs), which involved five interventions: Fast Track Initiation Counseling for newly initiating patients, Enhanced Adherence Counseling for patients with an unsuppressed viral load, Early Tracing of patients who miss visits, and Adherence Clubs (ACs) and Decentralized Medication Delivery (DMD) for stable patients. We evaluated two of these interventions in 24 South African facilities: ACs, in which patients meet in groups outside usual clinic procedures and receive medication; and DMD, in which patients pick up their medication outside usual pharmacy queues.Methods and Findings: We compared those participating in ACs or receiving DMD at intervention sites to those eligible for ACs or DMD at control sites. Outcomes were retention and sustained viral suppression (<400 copies/mL) 12 months after AC or DMD enrollment (or comparable time for controls). 12 facilities were randomly allocated to intervention and 12 to control arms in four provinces (Gauteng, North West, Limpopo, and KwaZulu Natal). We calculated adjusted risk differences (aRDs) with cluster adjustment using generalized estimating equations (GEEs) using difference in differences (DiD) with patients eligible for ACs/DMD prior to implementation (Jan 1, 2015) for comparison. For DMD, randomization was not preserved, and the analysis was treated as observational. For ACs, 275 intervention and 294 control patients were enrolled; 72% of patients were female, 61% were aged 30-49 years, and median CD4 count at ART initiation was 268 cells/μL. AC patients had higher 1-year retention (89.5% versus 81.6%, aRD: 8.3%; 95% CI: 1.1% to 15.6%) and comparable sustained 1-year viral suppression (<400 copies/mL any time ≤ 18 months) (80.0% versus 79.6%, aRD: 3.8%; 95% CI: -6.9% to 14.4%). Retention associations were apparently stronger for men than women (men RD: 13.1%, 95% CI: 0.3% to 23.5%; women RD: 6.0%, 95% CI: -0.9% to 12.9%). For DMD, 232 intervention and 346 control patients were enrolled; 71% of patients were female, 65% were aged 30-49 years, and median CD4 count at ART initiation was 270 cells/μL. DMD patients had apparently lower retention (81.5% versus 87.2%, aRD: -5.9%; 95% CI: -12.5% to 0.8%) and comparable viral suppression versus standard of care (77.2% versus 74.3%, aRD: -1.0%; 95% CI: -12.2% to 10.1%), though in both cases, our findings were imprecise. We also noted apparently increased viral suppression among men (RD: 11.1%; 95% CI: -3.4% to 25.5%). The main study limitations were missing data and lack of randomization in the DMD analysis.Conclusions: In this study, we found comparable DMD outcomes versus standard of care at facilities, a benefit for retention of patients in care with ACs, and apparent benefits in terms of retention (for AC patients) and sustained viral suppression (for DMD patients) among men. This suggests the importance of alternative service delivery models for men and of community-based strategies to decongest primary healthcare facilities. Because these strategies also reduce patient inconvenience and decongest clinics, comparable outcomes are a potential success. The cost of all five AGL interventions and possible effects on reducing clinic congestion should be investigated.Clinical Trial Registration: NCT02536768. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
9. Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness.
- Author
-
Olliaro, Piero L. and Vaillant, Michel
- Abstract
In this Collection Review for the Novel Treatments for Tuberculosis Collection, Piero Olliaro and Michael Vaillant discuss the considerations when choosing a non-inferiority margin that is meaningful from statistical, ethical, clinical, and health standpoint. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.
- Author
-
Davies, Geraint, Boeree, Martin, Hermann, Dave, and Hoelscher, Michael
- Subjects
TUBERCULOSIS ,NEW trials ,DESIGN & technology ,TECHNOLOGICAL innovations ,DRUG development - Abstract
Geraint Davies and colleagues discuss the potential for innovative early-phase clinical trial methods and technologies to reduce risk and speed up drug development for tuberculosis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.
- Author
-
Dooley, Kelly E., Hanna, Debra, Mave, Vidya, Eisenach, Kathleen, and Savic, Radojka M.
- Subjects
CLINICAL pharmacology ,MEDICAL microbiology ,THERAPEUTICS ,TUBERCULOSIS ,BIOMARKERS - Published
- 2019
- Full Text
- View/download PDF
12. Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
- Author
-
Phillips, Patrick P. J., Mitnick, Carole D., Neaton, James D., Nahid, Payam, Lienhardt, Christian, and Nunn, Andrew J.
- Subjects
TUBERCULOSIS ,LANDSCAPE changes ,BACTERIAL diseases - Abstract
In a Collection Review, Patrick Phillips and colleagues discuss developments in clinical trial design for the evaluation of TB therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. Advances in clinical trial design for development of new TB treatments: A call for innovation.
- Author
-
Lienhardt, Christian and Nahid, Payam
- Subjects
CLINICAL trials ,TUBERCULOSIS treatment ,BACTERIAL diseases ,MEDICAL sciences ,TROPICAL medicine - Abstract
Christian Lienhardt and Payam Nahid launch the Collection on Advances in Clinical Trial Design for Development of New Tuberculosis Treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Constructing care cascades for active tuberculosis: A strategy for program monitoring and identifying gaps in quality of care.
- Author
-
Subbaraman, Ramnath, Nathavitharana, Ruvandhi R., Mayer, Kenneth H., Satyanarayana, Srinath, Chadha, Vineet K., Arinaminpathy, Nimalan, and Pai, Madhukar
- Subjects
BACTERIAL diseases ,MEDICAL microbiology ,MEDICAL sciences ,TUBERCULOSIS ,LIFE sciences ,COMMUNICABLE diseases - Abstract
The cascade of care is a model for evaluating patient retention across sequential stages of care required to achieve a successful treatment outcome. This approach was first used to evaluate HIV care and has since been applied to other diseases. The tuberculosis (TB) community has only recently started using care cascade analyses to quantify gaps in quality of care. In this article, we describe methods for estimating gaps (patient losses) and steps (patients retained) in the care cascade for active TB disease. We highlight approaches for overcoming challenges in constructing the TB care cascade, which include difficulties in estimating the population-level burden of disease and the diagnostic gap due to the limited sensitivity of TB diagnostic tests. We also describe potential uses of this model for evaluating the impact of interventions to improve case finding, diagnosis, linkage to care, retention in care, and post-treatment monitoring of TB patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Setting targets for HIV/AIDS-What lessons can be learned from other disease control programmes?
- Author
-
Bhatia, Tazeem, Heymann, David, Dar, Osman, Enoch, Jamie, Khan, Mishal, Hayes, Richard, and Mathewson, Sophie
- Subjects
AIDS diagnosis ,AIDS prevention ,PREVENTION of epidemics ,DIAGNOSIS of HIV infections ,HIV prevention ,HANSEN'S disease diagnosis ,MALARIA diagnosis ,MALARIA prevention ,HIV infection epidemiology ,AIDS ,COMPARATIVE studies ,HANSEN'S disease ,MALARIA ,RESEARCH methodology ,MEDICAL care ,MEDICAL cooperation ,RESEARCH ,EVALUATION research ,DISEASE eradication - Abstract
In a Collection Review, Richard Hayes and colleagues discuss metrics for assessing progress in control of the HIV/AIDS epidemic in the context of prior disease control programmes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Variations in the quality of tuberculosis care in urban India: A cross-sectional, standardized patient study in two cities.
- Author
-
Kwan, Ada, Daniels, Benjamin, Saria, Vaibhav, Satyanarayana, Srinath, Subbaraman, Ramnath, McDowell, Andrew, Bergkvist, Sofi, Das, Ranendra K., Das, Veena, Das, Jishnu, and Pai, Madhukar
- Subjects
TUBERCULOSIS ,MEDICAL care ,ANALYSIS of variance ,X-rays ,RADIOGRAPHY - Abstract
Background: India has the highest burden of tuberculosis (TB). Although most patients with TB in India seek care from the private sector, there is limited evidence on quality of TB care or its correlates. Following our validation study on the standardized patient (SP) method for TB, we utilized SPs to examine quality of adult TB care among health providers with different qualifications in 2 Indian cities.Methods and Findings: During 2014-2017, pilot programs engaged the private health sector to improve TB management in Mumbai and Patna. Nested within these projects, to obtain representative, baseline measures of quality of TB care at the city level, we recruited 24 adults to be SPs. They were trained to portray 4 TB "case scenarios" representing various stages of disease and diagnostic progression. Between November 2014 and August 2015, the SPs visited representatively sampled private providers stratified by qualification: (1) allopathic providers with Bachelor of Medicine, Bachelor of Surgery (MBBS) degrees or higher and (2) non-MBBS providers with alternative medicine, minimal, or no qualifications. Our main outcome was case-specific correct management benchmarked against the Standards for TB Care in India (STCI). Using ANOVA, we assessed variation in correct management and quality outcomes across (a) cities, (b) qualifications, and (c) case scenarios. Additionally, 2 micro-experiments identified sources of variation: first, quality in the presence of diagnostic test results certainty and second, provider consistency for different patients presenting the same case. A total of 2,652 SP-provider interactions across 1,203 health facilities were analyzed. Based on our sampling strategy and after removing 50 micro-experiment interactions, 2,602 interactions were weighted for city-representative interpretation. After weighting, the 473 Patna providers receiving SPs represent 3,179 eligible providers in Patna; in Mumbai, the 730 providers represent 7,115 eligible providers. Correct management was observed in 959 out of 2,602 interactions (37%; 35% weighted; 95% CI 32%-37%), primarily from referrals and ordering chest X-rays (CXRs). Unnecessary medicines were given to nearly all SPs, and antibiotic use was common. Anti-TB drugs were prescribed in 118 interactions (4.5%; 5% weighted), of which 45 were given in the case in which such treatment is considered correct management. MBBS and more qualified providers had higher odds of correctly managing cases than non-MBBS providers (odds ratio [OR] 2.80; 95% CI 2.05-3.82; p < 0.0001). Mumbai non-MBBS providers had higher odds of correct management than non-MBBS in Patna (OR 1.79; 95% CI 1.06-3.03), and MBBS providers' quality of care did not vary between cities (OR 1.15; 95% CI 0.79-1.68; p = 0.4642). In the micro-experiments, improving diagnostic certainty had a positive effect on correct management but not across all quality dimensions. Also, providers delivered idiosyncratically consistent care, repeating all observed actions, including mistakes, approximately 75% of the time. The SP method has limitations: it cannot account for patient mix or care-management practices reflecting more than one patient-provider interaction.Conclusions: Quality of TB care is suboptimal and variable in urban India's private health sector. Addressing this is critical for India's plans to end TB by 2025. For the first time, we have rich measures on representative levels of care quality from 2 cities, which can inform private-sector TB interventions and quality-improvement efforts. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
17. Crowdsourcing to expand HIV testing among men who have sex with men in China: A closed cohort stepped wedge cluster randomized controlled trial.
- Author
-
Tang, Weiming, Wei, Chongyi, Cao, Bolin, Wu, Dan, Li, Katherine T., Lu, Haidong, Ma, Wei, Kang, Dianmin, Li, Haochu, Liao, Meizhen, Mollan, Katie R., Hudgens, Michael G., Liu, Chuncheng, Huang, Wenting, Liu, Aifeng, Zhang, Ye, Smith, M. Kumi, Mitchell, Kate M., Ong, Jason J., and Fu, Hongyun
- Subjects
CROWDSOURCING ,DIAGNOSIS of HIV infections ,MEN who have sex with men ,SOCIAL media mobile apps ,CONDOM use ,DISEASES - Abstract
Background: HIV testing rates are suboptimal among at-risk men. Crowdsourcing may be a useful tool for designing innovative, community-based HIV testing strategies to increase HIV testing. The purpose of this study was to use a stepped wedge cluster randomized controlled trial (RCT) to evaluate the effect of a crowdsourced HIV intervention on HIV testing uptake among men who have sex with men (MSM) in eight Chinese cities.Methods and Findings: An HIV testing intervention was developed through a national image contest, a regional strategy designathon, and local message contests. The final intervention included a multimedia HIV testing campaign, an online HIV testing service, and local testing promotion campaigns tailored for MSM. This intervention was evaluated using a closed cohort stepped wedge cluster RCT in eight Chinese cities (Guangzhou, Shenzhen, Zhuhai, and Jiangmen in Guangdong province; Jinan, Qingdao, Yantai, and Jining in Shandong province) from August 2016 to August 2017. MSM were recruited through Blued, a social networking mobile application for MSM, from July 29 to August 21 of 2016. The primary outcome was self-reported HIV testing in the past 3 months. Secondary outcomes included HIV self-testing, facility-based HIV testing, condom use, and syphilis testing. Generalized linear mixed models (GLMMs) were used to analyze primary and secondary outcomes. We enrolled a total of 1,381 MSM. Most were ≤30 years old (82%), unmarried (86%), and had a college degree or higher (65%). The proportion of individuals receiving an HIV test during the intervention periods within a city was 8.9% (95% confidence interval [CI] 2.2-15.5) greater than during the control periods. In addition, the intention-to-treat analysis showed a higher probability of receiving an HIV test during the intervention periods as compared to the control periods (estimated risk ratio [RR] = 1.43, 95% CI 1.19-1.73). The intervention also increased HIV self-testing (RR = 1.89, 95% CI 1.50-2.38). There was no effect on facility-based HIV testing (RR = 1.00, 95% CI 0.79-1.26), condom use (RR = 1.00, 95% CI 0.86-1.17), or syphilis testing (RR = 0.92, 95% CI 0.70-1.21). A total of 48.6% (593/1,219) of participants reported that they received HIV self-testing. Among men who received two HIV tests, 32 individuals seroconverted during the 1-year study period. Study limitations include the use of self-reported HIV testing data among a subset of men and non-completion of the final survey by 23% of participants. Our study population was a young online group in urban China and the relevance of our findings to other populations will require further investigation.Conclusions: In this setting, crowdsourcing was effective for developing and strengthening community-based HIV testing services for MSM. Crowdsourced interventions may be an important tool for the scale-up of HIV testing services among MSM in low- and middle-income countries (LMIC).Trial Registration: ClinicalTrials.gov NCT02796963. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
18. Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis.
- Author
-
McIntosh, Avery I., Jenkins, Helen E., White, Laura F., Barnard, Marinus, Thomson, Dana R., Dolby, Tania, Simpson, John, Streicher, Elizabeth M., Kleinman, Mary B., Ragan, Elizabeth J., van Helden, Paul D., Murray, Megan B., Warren, Robin M., and Jacobson, Karen R.
- Subjects
TUBERCULOSIS ,RIFAMPIN ,MICROBIOLOGY ,DRUG resistance ,PHARMACOLOGY - Abstract
Background: South Africa has the highest tuberculosis incidence globally (781/100,000), with an estimated 4.3% of cases being rifampicin resistant (RR). Control and elimination strategies will require detailed spatial information to understand where drug-resistant tuberculosis exists and why it persists in those communities. We demonstrate a method to enable drug-resistant tuberculosis monitoring by identifying high-burden communities in the Western Cape Province using routinely collected laboratory data.Methods and Findings: We retrospectively identified cases of microbiologically confirmed tuberculosis and RR-tuberculosis from all biological samples submitted for tuberculosis testing (n = 2,219,891) to the Western Cape National Health Laboratory Services (NHLS) between January 1, 2008, and June 30, 2013. Because the NHLS database lacks unique patient identifiers, we performed a series of record-linking processes to match specimen records to individual patients. We counted an individual as having a single disease episode if their positive samples came from within two years of each other. Cases were aggregated by clinic location (n = 302) to estimate the percentage of tuberculosis cases with rifampicin resistance per clinic. We used inverse distance weighting (IDW) to produce heatmaps of the RR-tuberculosis percentage across the province. Regression was used to estimate annual changes in the RR-tuberculosis percentage by clinic, and estimated average size and direction of change was mapped. We identified 799,779 individuals who had specimens submitted from mappable clinics for testing, of whom 222,735 (27.8%) had microbiologically confirmed tuberculosis. The study population was 43% female, the median age was 36 years (IQR 27-44), and 10,255 (4.6%, 95% CI: 4.6-4.7) cases had documented rifampicin resistance. Among individuals with microbiologically confirmed tuberculosis, 8,947 (4.0%) had more than one disease episode during the study period. The percentage of tuberculosis cases with rifampicin resistance documented among these individuals was 11.4% (95% CI: 10.7-12.0). Overall, the percentage of tuberculosis cases that were RR-tuberculosis was spatially heterogeneous, ranging from 0% to 25% across the province. Our maps reveal significant yearly fluctuations in RR-tuberculosis percentages at several locations. Additionally, the directions of change over time in RR-tuberculosis percentage were not uniform. The main limitation of this study is the lack of unique patient identifiers in the NHLS database, rendering findings to be estimates reliant on the accuracy of the person-matching algorithm.Conclusions: Our maps reveal striking spatial and temporal heterogeneity in RR-tuberculosis percentages across this province. We demonstrate the potential to monitor RR-tuberculosis spatially and temporally with routinely collected laboratory data, enabling improved resource targeting and more rapid locally appropriate interventions. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
19. Effect and cost-effectiveness of educating mothers about childhood DPT vaccination on immunisation uptake, knowledge, and perceptions in Uttar Pradesh, India: A randomised controlled trial.
- Author
-
Powell-Jackson, Timothy, Fabbri, Camilla, Dutt, Varun, Tougher, Sarah, and Singh, Kultar
- Subjects
DPT vaccines ,MOTHERS ,HEALTH education ,VACCINATION of children ,COST effectiveness - Abstract
Background: To assess the effect of health information on immunisation uptake in rural India, we conducted an individually randomised controlled trial of health information messages targeting the mothers of unvaccinated or incompletely vaccinated children through home visits in rural Uttar Pradesh, India.Methods and Findings: The study tested a brief intervention that provided mothers face-to-face with information on the benefits of the tetanus vaccine. Participants were 722 mothers of children aged 0-36 months who had not received 3 doses of diphtheria-pertussis-tetanus (DPT) vaccine (DPT3). Mothers were randomly assigned in a ratio of 1:1:1 to 1 of 3 study arms: mothers in the first treatment group received information framed as a gain (e.g., the child is less likely to get tetanus and more likely to be healthy if vaccinated), mothers in the second treatment group received information framed in terms of a loss (e.g., the child is more likely to get tetanus and suffer ill health if not vaccinated), and the third arm acted as a control group, with no information given to the mother. Surveys were conducted at baseline (September 2015) and after the intervention (April 2016). The primary outcome was the proportion of children who had received DPT3 measured after 7 months of follow-up. The analysis was by intention to treat. A total of 16 (2.2%) participants were lost to follow-up. The coverage of DPT3 was 28% in the control group and 43% in the pooled information groups, giving a risk difference of 15 percentage points (95% CI: 7% to 22%, p < 0.001) and a relative risk of 1.52 (95% CI: 1.2 to 1.9, p < 0.001). The information intervention increased the rate of measles vaccination by 22 percentage points (risk difference: 22%, 95% CI: 14% to 30%, p < 0.001; relative risk: 1.53, 95% CI: 1.29 to 1.80) and the rate of full immunisation by 14 percentage points (risk difference: 14%, 95% CI: 8% to 21%, p < 0.001; relative risk: 1.72, 95% CI: 1.29 to 2.29). It had a large positive effect on knowledge of the causes, symptoms, and prevention of tetanus but no effect on perceptions of vaccine efficacy. There was no difference in the proportion of children with DPT3 between the group that received information framed as a loss and the group that received information framed as a gain (risk difference: 4%, 95% CI: -5% to 13%; p = 0.352; relative risk: 1.11, 95% CI: 0.90 to 1.36). The cost per disability-adjusted life year averted of providing information was US$186, making the intervention highly cost-effective with respect to the WHO-recommended threshold of once the gross domestic product per capita (US$793 in the case of Uttar Pradesh). Key study limitations include the modest sample size for this trial, limiting power to detect small differences in the framing of information, and the potential for contamination among households.Conclusions: Providing mothers of unvaccinated/incompletely vaccinated children with information on tetanus and the benefits of DPT vaccination substantially increased immunisation coverage and was highly cost-effective. The framing of the health information message did not appear to matter.Trial Registration: The trial is registered with ISRCTN, number ISRCTN84560580. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
20. The potential impact of case-area targeted interventions in response to cholera outbreaks: A modeling study.
- Author
-
Finger, Flavio, Bertuzzo, Enrico, Luquero, Francisco J., Naibei, Nathan, Touré, Brahima, Allan, Maya, Porten, Klaudia, Lessler, Justin, Rinaldo, Andrea, and Azman, Andrew S.
- Subjects
PREVENTION of cholera ,CHOLERA vaccines ,SANITATION ,ANTIBIOTICS ,VIBRIO cholerae ,CHOLERA treatment ,WATER supply ,CHOLERA ,COMPARATIVE studies ,COMPUTER simulation ,DISEASE outbreaks ,HEALTH planning ,MATHEMATICAL models ,RESEARCH methodology ,MEDICAL needs assessment ,MEDICAL cooperation ,POPULATION geography ,RESEARCH ,THEORY ,EVALUATION research ,SOCIAL services case management ,THERAPEUTICS ,STANDARDS - Abstract
Background: Cholera prevention and control interventions targeted to neighbors of cholera cases (case-area targeted interventions [CATIs]), including improved water, sanitation, and hygiene, oral cholera vaccine (OCV), and prophylactic antibiotics, may be able to efficiently avert cholera cases and deaths while saving scarce resources during epidemics. Efforts to quickly target interventions to neighbors of cases have been made in recent outbreaks, but little empirical evidence related to the effectiveness, efficiency, or ideal design of this approach exists. Here, we aim to provide practical guidance on how CATIs might be used by exploring key determinants of intervention impact, including the mix of interventions, "ring" size, and timing, in simulated cholera epidemics fit to data from an urban cholera epidemic in Africa.Methods and Findings: We developed a micro-simulation model and calibrated it to both the epidemic curve and the small-scale spatiotemporal clustering pattern of case households from a large 2011 cholera outbreak in N'Djamena, Chad (4,352 reported cases over 232 days), and explored the potential impact of CATIs in simulated epidemics. CATIs were implemented with realistic logistical delays after cases presented for care using different combinations of prophylactic antibiotics, OCV, and/or point-of-use water treatment (POUWT) starting at different points during the epidemics and targeting rings of various radii around incident case households. Our findings suggest that CATIs shorten the duration of epidemics and are more resource-efficient than mass campaigns. OCV was predicted to be the most effective single intervention, followed by POUWT and antibiotics. CATIs with OCV started early in an epidemic focusing on a 100-m radius around case households were estimated to shorten epidemics by 68% (IQR 62% to 72%), with an 81% (IQR 69% to 87%) reduction in cases compared to uncontrolled epidemics. These same targeted interventions with OCV led to a 44-fold (IQR 27 to 78) reduction in the number of people needed to target to avert a single case of cholera, compared to mass campaigns in high-cholera-risk neighborhoods. The optimal radius to target around incident case households differed by intervention type, with antibiotics having an optimal radius of 30 m to 45 m compared to 70 m to 100 m for OCV and POUWT. Adding POUWT or antibiotics to OCV provided only marginal impact and efficiency improvements. Starting CATIs early in an epidemic with OCV and POUWT targeting those within 100 m of an incident case household reduced epidemic durations by 70% (IQR 65% to 75%) and the number of cases by 82% (IQR 71% to 88%) compared to uncontrolled epidemics. CATIs used late in epidemics, even after the peak, were estimated to avert relatively few cases but substantially reduced the number of epidemic days (e.g., by 28% [IQR 15% to 45%] for OCV in a 100-m radius). While this study is based on a rigorous, data-driven approach, the relatively high uncertainty about the ways in which POUWT and antibiotic interventions reduce cholera risk, as well as the heterogeneity in outbreak dynamics from place to place, limits the precision and generalizability of our quantitative estimates.Conclusions: In this study, we found that CATIs using OCV, antibiotics, and water treatment interventions at an appropriate radius around cases could be an effective and efficient way to fight cholera epidemics. They can provide a complementary and efficient approach to mass intervention campaigns and may prove particularly useful during the initial phase of an outbreak, when there are few cases and few available resources, or in order to shorten the often protracted tails of cholera epidemics. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
21. Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies.
- Author
-
Torrone, Elizabeth A., Morrison, Charles S., Chen, Pai-Lien, Kwok, Cynthia, Francis, Suzanna C., Hayes, Richard J., Looker, Katharine J., McCormack, Sheena, McGrath, Nuala, van de Wijgert, Janneke H. H. M., Watson-Jones, Deborah, Low, Nicola, Gottlieb, Sami L., null, null, and STIMA Working Group
- Subjects
SEXUALLY transmitted diseases ,BACTERIAL vaginitis ,DISEASE prevalence ,HIV prevention ,GONORRHEA ,EPIDEMIOLOGY of sexually transmitted diseases ,HIV infection epidemiology ,COMPARATIVE studies ,HEALTH promotion ,HIV ,RESEARCH methodology ,MEDICAL cooperation ,META-analysis ,RESEARCH ,RESEARCH funding ,EVALUATION research - Abstract
Background: Estimates of sexually transmitted infection (STI) prevalence are essential for efforts to prevent and control STIs. Few large STI prevalence studies exist, especially for low- and middle-income countries (LMICs). Our primary objective was to estimate the prevalence of chlamydia, gonorrhea, trichomoniasis, syphilis, herpes simplex virus type 2 (HSV-2), and bacterial vaginosis (BV) among women in sub-Saharan Africa by age, region, and population type.Methods and Findings: We analyzed individual-level data from 18 HIV prevention studies (cohort studies and randomized controlled trials; conducted during 1993-2011), representing >37,000 women, that tested participants for ≥1 selected STIs or BV at baseline. We used a 2-stage meta-analysis to combine data. After calculating the proportion of participants with each infection and standard error by study, we used a random-effects model to obtain a summary mean prevalence of each infection and 95% confidence interval (CI) across ages, regions, and population types. Despite substantial study heterogeneity for some STIs/populations, several patterns emerged. Across the three primary region/population groups (South Africa community-based, Southern/Eastern Africa community-based, and Eastern Africa higher-risk), prevalence was higher among 15-24-year-old than 25-49-year-old women for all STIs except HSV-2. In general, higher-risk populations had greater prevalence of gonorrhea and syphilis than clinic/community-based populations. For chlamydia, prevalence among 15-24-year-olds was 10.3% (95% CI: 7.4%, 14.1%; I2 = 75.7%) among women specifically recruited from higher-risk settings for HIV in Eastern Africa and was 15.1% (95% CI: 12.7%, 17.8%; I2 = 82.3%) in South African clinic/community-based populations. Among clinic/community-based populations, prevalence was generally greater in South Africa than in Southern/Eastern Africa for most STIs; for gonorrhea, prevalence among 15-24-year-olds was 4.6% (95% CI: 3.3%, 6.4%; I2 = 82.8%) in South Africa and was 1.7% (95% CI: 1.2%, 2.6%; I2 = 55.2%) in Southern/Eastern Africa. Across the three primary region/population groups, HSV-2 and BV prevalence was high among 25-49-year-olds (ranging from 70% to 83% and 33% to 44%, respectively). The main study limitation is that the data are not from random samples of the target populations.Conclusions: Combining data from 18 HIV prevention studies, our findings highlight important features of STI/BV epidemiology among sub-Saharan African women. This methodology can be used where routine STI surveillance is limited and offers a new approach to obtaining critical information on STI and BV prevalence in LMICs. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
22. Prevalence of sexually transmitted infections among young people in South Africa: A nested survey in a health and demographic surveillance site.
- Author
-
Francis, Suzanna C., Mthiyane, T. Nondumiso, Baisley, Kathy, Mchunu, S. Lerato, Ferguson, Jane B., Smit, Theresa, Crucitti, Tania, Gareta, Dickman, Dlamini, Siphephelo, Mutevedzi, Tinofa, Seeley, Janet, Pillay, Deenan, McGrath, Nuala, and Shahmanesh, Maryam
- Subjects
SEXUALLY transmitted diseases ,BACTERIAL vaginitis ,DISEASE prevalence ,HIV infection transmission ,SYPHILIS ,EPIDEMIOLOGY of sexually transmitted diseases ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,PUBLIC health surveillance ,RESEARCH ,RESEARCH funding ,EVALUATION research ,CROSS-sectional method - Abstract
Background: Sexually transmitted infections (STIs) and bacterial vaginosis (BV) are associated with increased transmission of HIV, and poor reproductive and sexual health. The burden of STIs/BV among young people is unknown in many high HIV prevalence settings. We conducted an acceptability, feasibility, and prevalence study of home-based sampling for STIs/BV among young men and women aged 15-24 years old in a health and demographic surveillance site (HDSS) in rural KwaZulu-Natal, South Africa.Methods and Findings: A total of 1,342 young people, stratified by age (15-19 and 20-24 years) and sex were selected from the HDSS sampling frame; 1,171/1,342 (87%) individuals had ≥1 attempted home visit between 4 October 2016 and 31 January 2017, of whom 790 (67%) were successfully contacted. Among the 645 who were contacted and eligible, 447 (69%) enrolled. Consenting/assenting participants were interviewed, and blood, self-collected urine (men), and vaginal swabs (women) were tested for herpes simplex virus type 2 (HSV-2), chlamydia, gonorrhoea, syphilis, trichomoniasis, and BV. Both men and women reported that sample collection was easy. Participants disagreed that sampling was painful; more than half of the participants disagreed that they felt anxious or embarrassed. The weighted prevalence of STIs/BV among men and women, respectively, was 5.3% and 11.2% for chlamydia, 1.5% and 1.8% for gonorrhoea, 0% and 0.4% for active syphilis, 0.6% and 4.6% for trichomoniasis, 16.8% and 28.7% for HSV-2, and 42.1% for BV (women only). Of the women with ≥1 curable STI, 75% reported no symptoms. Factors associated with STIs/BV included having older age, being female, and not being in school or working. Among those who participated in the 2016 HIV serosurvey, the prevalence of HIV was 5.6% among men and 19% among women. Feasibility was impacted by the short study duration and the difficulty finding men at home.Conclusions: A high prevalence of STIs/BV was found in this rural setting with high HIV prevalence in South Africa. Most STIs and HIV infections were asymptomatic and would not have been identified or treated under national syndromic management guidelines. A nested STI/BV survey within a HDSS proved acceptable and feasible. This is a proof of concept for population-based STI surveillance in low- and middle-income countries that could be utilised in the evaluation of STI/HIV prevention and control programmes. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
23. Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: An evaluation from multi-country surveys and stakeholder interviews.
- Author
-
Nurse-Findlay, Stephen, Taylor, Melanie M., Savage, Margaret, Mello, Maeve B., Saliyou, Sanni, Lavayen, Manuel, Seghers, Frederic, Campbell, Michael L., Birgirimana, Françoise, Ouedraogo, Leopold, Newman Owiredu, Morkor, Kidula, Nancy, and Pyne-Mercier, Lee
- Subjects
SYPHILIS ,PENICILLIN ,VERTICAL transmission (Communicable diseases) ,ANTIBIOTICS ,INFECTIOUS disease transmission ,PREVENTION ,CONGENITAL, hereditary, & infantile syphilis ,COMMUNICABLE diseases ,COMPARATIVE studies ,HEALTH promotion ,RESEARCH methodology ,MEDICAL cooperation ,POPULATION geography ,PREGNANCY complications ,PUBLIC health ,RESEARCH ,RESEARCH funding ,WORLD health ,EVALUATION research ,PENICILLIN G ,THERAPEUTICS - Abstract
Background: Benzathine penicillin G (BPG) is the only recommended treatment to prevent mother-to-child transmission of syphilis. Due to recent reports of country-level shortages of BPG, an evaluation was undertaken to quantify countries that have experienced shortages in the past 2 years and to describe factors contributing to these shortages.Methods and Findings: Country-level data about BPG shortages were collected using 3 survey approaches. First, a survey designed by the WHO Department of Reproductive Health and Research was distributed to 41 countries and territories in the Americas and 41 more in Africa. Second, WHO conducted an email survey of 28 US Centers for Disease Control and Prevention country directors. An additional 13 countries were in contact with WHO for related congenital syphilis prevention activities and also reported on BPG shortages. Third, the Clinton Health Access Initiative (CHAI) collected data from 14 countries (where it has active operations) to understand the extent of stock-outs, in-country purchasing, usage behavior, and breadth of available purchasing options to identify stock-outs worldwide. CHAI also conducted in-person interviews in the same 14 countries to understand the extent of stock-outs, in-country purchasing and usage behavior, and available purchasing options. CHAI also completed a desk review of 10 additional high-income countries, which were also included. BPG shortages were attributable to shortfalls in supply, demand, and procurement in the countries assessed. This assessment should not be considered globally representative as countries not surveyed may also have experienced BPG shortages. Country contacts may not have been aware of BPG shortages when surveyed or may have underreported medication substitutions due to desirability bias. Funding for the purchase of BPG by countries was not evaluated. In all, 114 countries and territories were approached to provide information on BPG shortages occurring during 2014-2016. Of unique countries and territories, 95 (83%) responded or had information evaluable from public records. Of these 95 countries and territories, 39 (41%) reported a BPG shortage, and 56 (59%) reported no BPG shortage; 10 (12%) countries with and without BPG shortages reported use of antibiotic alternatives to BPG for treatment of maternal syphilis. Market exits, inflexible production cycles, and minimum order quantities affect BPG supply. On the demand side, inaccurate forecasts and sole sourcing lead to under-procurement. Clinicians may also incorrectly prescribe BPG substitutes due to misperceptions of quality or of the likelihood of adverse outcomes.Conclusions: Targets for improvement include drug forecasting and procurement, and addressing provider reluctance to use BPG. Opportunities to improve global supply, demand, and use of BPG should be prioritized alongside congenital syphilis elimination efforts. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
24. Measuring success: The challenge of social protection in helping eliminate tuberculosis.
- Author
-
Shete, Priya B. and Dowdy, David W.
- Subjects
TUBERCULOSIS treatment ,TUBERCULOSIS ,SOCIAL services ,SOCIAL impact ,FINANCIAL aid ,HEALTH programs - Abstract
In this Perspective on the research article by William Rudgard and colleagues, Priya Shete and coauthor discuss the challenges of measuring the impact of social protection programs such as cash transfers. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
25. Contemporary disengagement from antiretroviral therapy in Khayelitsha, South Africa: A cohort study.
- Author
-
Kaplan, Samantha R., Oosthuizen, Christa, Stinson, Kathryn, Little, Francesca, Euvrard, Jonathan, Schomaker, Michael, Osler, Meg, Hilderbrand, Katherine, Boulle, Andrew, and Meintjes, Graeme
- Subjects
THERAPEUTICS ,HIV infections ,HIGHLY active antiretroviral therapy ,PROPORTIONAL hazards models ,HEALTH outcome assessment ,HIV-positive persons ,MEDICAL care ,ANTIRETROVIRAL agents ,HIV infection epidemiology ,AGE distribution ,DRUGS ,PATIENT compliance ,SEX distribution ,DISEASE incidence ,ACQUISITION of data ,RETROSPECTIVE studies ,PATIENTS' attitudes - Abstract
Background: Retention in care is an essential component of meeting the UNAIDS "90-90-90" HIV treatment targets. In Khayelitsha township (population ~500,000) in Cape Town, South Africa, more than 50,000 patients have received antiretroviral therapy (ART) since the inception of this public-sector program in 2001. Disengagement from care remains an important challenge. We sought to determine the incidence of and risk factors associated with disengagement from care during 2013-2014 and outcomes for those who disengaged.Methods and Findings: We conducted a retrospective cohort study of all patients ≥10 years of age who visited 1 of the 13 Khayelitsha ART clinics from 2013-2014 regardless of the date they initiated ART. We described the cumulative incidence of first disengagement (>180 days not attending clinic) between 1 January 2013 and 31 December 2014 using competing risks methods, enabling us to estimate disengagement incidence up to 10 years after ART initiation. We also described risk factors for disengagement based on a Cox proportional hazards model, using multiple imputation for missing data. We ascertained outcomes (death, return to care, hospital admission, other hospital contact, alive but not in care, no information) after disengagement until 30 June 2015 using province-wide health databases and the National Death Registry. Of 39,884 patients meeting our eligibility criteria, the median time on ART to 31 December 2014 was 33.6 months (IQR 12.4-63.2). Of the total study cohort, 592 (1.5%) died in the study period, 1,231 (3.1%) formally transferred out, 987 (2.5%) were silent transfers and visited another Western Cape province clinic within 180 days, 9,005 (22.6%) disengaged, and 28,069 (70.4%) remained in care. Cumulative incidence of disengagement from care was estimated to be 25.1% by 2 years and 50.3% by 5 years on ART. Key factors associated with disengagement (age, male sex, pregnancy at ART start [HR 1.58, 95% CI 1.47-1.69], most recent CD4 count) and retention (ART club membership, baseline CD4) after adjustment were similar to those found in previous studies; however, notably, the higher hazard of disengagement soon after starting ART was no longer present after adjusting for these risk factors. Of the 9,005 who disengaged, the 2 most common initial outcomes were return to ART care after 180 days (33%; n = 2,976) and being alive but not in care in the Western Cape (25%; n = 2,255). After disengagement, a total of 1,459 (16%) patients were hospitalized and 237 (3%) died. The median follow-up from date of disengagement to 30 June 2015 was 16.7 months (IQR 11-22.4). As we included only patient follow-up from 2013-2014 by design in order to maximize the generalizability of our findings to current programs, this limited our ability to more fully describe temporal trends in first disengagement.Conclusions: Twenty-three percent of ART patients in the large cohort of Khayelitsha, one of the oldest public-sector ART programs in South Africa, disengaged from care at least once in a contemporary 2-year period. Fifty-eight percent of these patients either subsequently returned to care (some "silently") or remained alive without hospitalization, suggesting that many who are considered "lost" actually return to care, and that misclassification of "lost" patients is likely common in similar urban populations. A challenge to meeting ART retention targets is developing, testing, and implementing program designs to target mobile populations and retain them in lifelong care. This should be guided by risk factors for disengagement and improving interlinkage of routine information systems to better support patient care across complex care platforms. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
26. Comparison of two cash transfer strategies to prevent catastrophic costs for poor tuberculosis-affected households in low- and middle-income countries: An economic modelling study.
- Author
-
Rudgard, William E., Evans, Carlton A., Sweeney, Sedona, Wingfield, Tom, Lönnroth, Knut, Barreira, Draurio, and Boccia, Delia
- Subjects
TUBERCULOSIS patients ,HOUSEHOLD budgets ,HEALTH programs ,POVERTY reduction ,ECONOMIC models ,MIDDLE-income countries ,TREATMENT effectiveness ,LOW-income countries ,TUBERCULOSIS prevention ,TUBERCULOSIS ,POVERTY areas ,ANTITUBERCULAR agents ,COMPARATIVE studies ,DEVELOPING countries ,INCOME ,RESEARCH methodology ,MEDICAL care costs ,MEDICAL cooperation ,RESEARCH ,RESEARCH funding ,SOCIOECONOMIC factors ,EVALUATION research ,AT-risk people ,STATISTICAL models ,ECONOMICS - Abstract
Background: Illness-related costs for patients with tuberculosis (TB) ≥20% of pre-illness annual household income predict adverse treatment outcomes and have been termed "catastrophic." Social protection initiatives, including cash transfers, are endorsed to help prevent catastrophic costs. With this aim, cash transfers may either be provided to defray TB-related costs of households with a confirmed TB diagnosis (termed a "TB-specific" approach); or to increase income of households with high TB risk to strengthen their economic resilience (termed a "TB-sensitive" approach). The impact of cash transfers provided with each of these approaches might vary. We undertook an economic modelling study from the patient perspective to compare the potential of these 2 cash transfer approaches to prevent catastrophic costs.Methods and Findings: Model inputs for 7 low- and middle-income countries (Brazil, Colombia, Ecuador, Ghana, Mexico, Tanzania, and Yemen) were retrieved by literature review and included countries' mean patient TB-related costs, mean household income, mean cash transfers, and estimated TB-specific and TB-sensitive target populations. Analyses were completed for drug-susceptible (DS) TB-related costs in all 7 out of 7 countries, and additionally for drug-resistant (DR) TB-related costs in 1 of the 7 countries with available data. All cost data were reported in 2013 international dollars ($). The target population for TB-specific cash transfers was poor households with a confirmed TB diagnosis, and for TB-sensitive cash transfers was poor households already targeted by countries' established poverty-reduction cash transfer programme. Cash transfers offered in countries, unrelated to TB, ranged from $217 to $1,091/year/household. Before cash transfers, DS TB-related costs were catastrophic in 6 out of 7 countries. If cash transfers were provided with a TB-specific approach, alone they would be insufficient to prevent DS TB catastrophic costs in 4 out of 6 countries, and when increased enough to prevent DS TB catastrophic costs would require a budget between $3.8 million (95% CI: $3.8 million-$3.8 million) and $75 million (95% CI: $50 million-$100 million) per country. If instead cash transfers were provided with a TB-sensitive approach, alone they would be insufficient to prevent DS TB-related catastrophic costs in any of the 6 countries, and when increased enough to prevent DS TB catastrophic costs would require a budget between $298 million (95% CI: $219 million-$378 million) and $165,367 million (95% CI: $134,085 million-$196,425 million) per country. DR TB-related costs were catastrophic before and after TB-specific or TB-sensitive cash transfers in 1 out of 1 countries. Sensitivity analyses showed our findings to be robust to imputation of missing TB-related cost components, and use of 10% or 30% instead of 20% as the threshold for measuring catastrophic costs. Key limitations were using national average data and not considering other health and social benefits of cash transfers.Conclusions: A TB-sensitive cash transfer approach to increase all poor households' income may have broad benefits by reducing poverty, but is unlikely to be as effective or affordable for preventing TB catastrophic costs as a TB-specific cash transfer approach to defray TB-related costs only in poor households with a confirmed TB diagnosis. Preventing DR TB-related catastrophic costs will require considerable additional investment whether a TB-sensitive or a TB-specific cash transfer approach is used. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
27. An open source pharma roadmap.
- Author
-
Balasegaram, Manica, Kolb, Peter, McKew, John, Menon, Jaykumar, Olliaro, Piero, Sablinski, Tomasz, Thomas, Zakir, Todd, Matthew H., Torreele, Els, and Wilbanks, John
- Subjects
DRUG development ,OPEN source software ,INFORMATION & communication technologies ,PHARMACEUTICAL research - Abstract
In an Essay, Matthew Todd and colleagues discuss an open source approach to drug development. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
- Author
-
Cox, Helen, Dickson-Hall, Lindy, Ndjeka, Norbert, van’t Hoog, Anja, Grant, Alison, Cobelens, Frank, Stevens, Wendy, Nicol, Mark, and Van't Hoog, Anja
- Subjects
RIFAMPIN ,TUBERCULOSIS patients ,TUBERCULOSIS treatment ,TUBERCULOSIS diagnosis - Abstract
Background: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,734 patients diagnosed in 2014. The number of diagnosed patients has increased substantially with the introduction of the Xpert MTB/RIF test, used for tuberculosis (TB) diagnosis for all patients with presumptive TB. Routine aggregate data suggest a large treatment gap (pre-treatment loss to follow-up) between the numbers of patients with laboratory-confirmed RR-TB and those reported to have started second-line treatment. We aimed to assess the impact of Xpert MTB/RIF implementation on the delay to treatment initiation and loss to follow-up before second-line treatment for RR-TB across South Africa.Methods and Findings: A nationwide retrospective cohort study was conducted to assess second-line treatment initiation and treatment delay among laboratory-diagnosed RR-TB patients. Cohorts, including approximately 300 sequentially diagnosed RR-TB patients per South African province, were drawn from the years 2011 and 2013, i.e., before and after Xpert implementation. Patients with prior laboratory RR-TB diagnoses within 6 mo and currently treated patients were excluded. Treatment initiation was determined through data linkage with national and local treatment registers, medical record review, interviews with health care staff, and direct contact with patients or household members. Additional laboratory data were used to track cases. National estimates of the percentage of patients who initiated treatment and time to treatment were weighted to account for the sampling design. There were 2,508 and 2,528 eligible patients in the 2011 and 2013 cohorts, respectively; 92% were newly diagnosed with RR-TB (no prior RR-TB diagnoses). Nationally, among the 2,340 and 2,311 new RR-TB patients in the 2011 and 2013 cohorts, 55% (95% CI 53%-57%) and 63% (95% CI 61%-65%), respectively, started treatment within 6 mo of laboratory receipt of their diagnostic specimen (p < 0.001). However, in 2013, there was no difference in the percentage of patients who initiated treatment at 6 mo between the 1,368 new RR-TB patients diagnosed by Xpert (62%, 95% CI 59%-65%) and the 943 diagnosed by other methods (64%, 95% CI 61%-67%) (p = 0.39). The median time to treatment decreased from 44 d (interquartile range [IQR] 20-69) in 2011 to 22 d (IQR 2-43) in 2013 (p < 0.001). In 2013, across the nine provinces, there were substantial variations in both treatment initiation (range 51%-73% by 6 mo) and median time to treatment (range 15-36 d, n = 1,450), and only 53% of the 1,448 new RR-TB patients who received treatment were recorded in the national RR-TB register. This retrospective study is limited by the lack of information to assess reasons for non-initiation of treatment, particularly pre-treatment mortality data. Other limitations include the use of names and dates of birth to locate patient-level data, potentially resulting in missed treatment initiation among some patients.Conclusions: In 2013, there was a large treatment gap for RR-TB in South Africa that varied significantly across provinces. Xpert implementation, while reducing treatment delay, had not contributed substantially to reducing the treatment gap in 2013. However, given improved case detection with Xpert, a larger proportion of RR-TB patients overall have received treatment, with reduced delays. Nonetheless, strategies to further improve linkage to treatment for all diagnosed RR-TB patients are urgently required. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
29. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.
- Author
-
Houben, Rein M. G. J. and Dodd, Peter J.
- Subjects
TUBERCULOSIS ,MYCOBACTERIAL diseases ,TUBERCULOSIS diagnosis ,TUBERCULOSIS treatment ,TUBERCULOSIS microbiology ,TUBERCULOSIS epidemiology ,ANTITUBERCULAR agents ,ISONIAZID ,MYCOBACTERIUM tuberculosis ,WORLD health ,RELATIVE medical risk ,DISEASE incidence ,DISEASE prevalence ,PHARMACODYNAMICS ,PHYSIOLOGY - Abstract
Background: The existing estimate of the global burden of latent TB infection (LTBI) as "one-third" of the world population is nearly 20 y old. Given the importance of controlling LTBI as part of the End TB Strategy for eliminating TB by 2050, changes in demography and scientific understanding, and progress in TB control, it is important to re-assess the global burden of LTBI.Methods and Findings: We constructed trends in annual risk in infection (ARI) for countries between 1934 and 2014 using a combination of direct estimates of ARI from LTBI surveys (131 surveys from 1950 to 2011) and indirect estimates of ARI calculated from World Health Organisation (WHO) estimates of smear positive TB prevalence from 1990 to 2014. Gaussian process regression was used to generate ARIs for country-years without data and to represent uncertainty. Estimated ARI time-series were applied to the demography in each country to calculate the number and proportions of individuals infected, recently infected (infected within 2 y), and recently infected with isoniazid (INH)-resistant strains. Resulting estimates were aggregated by WHO region. We estimated the contribution of existing infections to TB incidence in 2035 and 2050. In 2014, the global burden of LTBI was 23.0% (95% uncertainty interval [UI]: 20.4%-26.4%), amounting to approximately 1.7 billion people. WHO South-East Asia, Western-Pacific, and Africa regions had the highest prevalence and accounted for around 80% of those with LTBI. Prevalence of recent infection was 0.8% (95% UI: 0.7%-0.9%) of the global population, amounting to 55.5 (95% UI: 48.2-63.8) million individuals currently at high risk of TB disease, of which 10.9% (95% UI:10.2%-11.8%) was isoniazid-resistant. Current LTBI alone, assuming no additional infections from 2015 onwards, would be expected to generate TB incidences in the region of 16.5 per 100,000 per year in 2035 and 8.3 per 100,000 per year in 2050. Limitations included the quantity and methodological heterogeneity of direct ARI data, and limited evidence to inform on potential clearance of LTBI.Conclusions: We estimate that approximately 1.7 billion individuals were latently infected with Mycobacterium tuberculosis (M.tb) globally in 2014, just under a quarter of the global population. Investment in new tools to improve diagnosis and treatment of those with LTBI at risk of progressing to disease is urgently needed to address this latent reservoir if the 2050 target of eliminating TB is to be reached. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
30. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
- Author
-
Kunkel, Amber, Cobelens, Frank G., and Cohen, Ted
- Subjects
TUBERCULOSIS treatment ,CHEST diseases ,LUNG diseases ,MYCOBACTERIAL diseases ,MEDICAL care - Abstract
Background: New drugs for the treatment of tuberculosis (TB) are becoming available for the first time in over 40 y. Optimal strategies for introducing these drugs have not yet been established. The objective of this study was to compare different strategies for introducing the new TB drug bedaquiline based on patients' resistance patterns.Methods and Findings: We created a Markov decision model to follow a hypothetical cohort of multidrug-resistant (MDR) TB patients under different bedaquiline use strategies. The explored strategies included making bedaquiline available to all patients with MDR TB, restricting bedaquiline usage to patients with MDR plus additional resistance and withholding bedaquiline introduction completely. We compared these strategies according to life expectancy, risks of acquired resistance, and the expected number and health outcomes of secondary cases. For our simulated cohort, the mean (2.5th, 97.5th percentile) life expectancy from time of initiation of MDR TB treatment at age 30 was 36.0 y (33.5, 38.7) assuming all patients with MDR TB received bedaquiline, 35.1 y (34.4, 35.8) assuming patients with pre-extensively drug-resistant (PreXDR) and extensively drug-resistant (XDR) TB received bedaquiline, and 34.9 y (34.6, 35.2) assuming only patients with XDR TB received bedaquiline. Although providing bedaquiline to all MDR patients resulted in the highest life expectancy for our initial cohort averaged across all parameter sets, for parameter sets in which bedaquiline conferred high risks of added mortality and only small reductions in median time to culture conversion, the optimal strategy would be to withhold use even from patients with the most extensive resistance. Across all parameter sets, the most liberal bedaquiline use strategies consistently increased the risk of bedaquiline resistance but decreased the risk of resistance to other MDR drugs. In almost all cases, more liberal bedaquiline use strategies reduced the expected number of secondary cases and resulting life years lost. The generalizability of our results is limited by the lack of available data about drug effects among individuals with HIV co-infection, drug interactions, and other sources of heterogeneity, as well as changing recommendations for MDR TB treatment.Conclusions: If mortality benefits can be empirically verified, our results provide support for expanding bedaquiline access to all patients with MDR TB. Such expansion could improve patients' health, protect background MDR TB drugs, and decrease transmission, but would likely result in greater resistance to bedaquiline. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
31. Potential for Controlling Cholera Using a Ring Vaccination Strategy: Re-analysis of Data from a Cluster-Randomized Clinical Trial.
- Author
-
Ali, Mohammad, Debes, Amanda K., Luquero, Francisco J., Kim, Deok Ryun, Park, Je Yeon, Digilio, Laura, Manna, Byomkesh, Kanungo, Suman, Dutta, Shanta, Sur, Dipika, Bhattacharya, Sujit K., and Sack, David A.
- Subjects
VACCINE effectiveness ,CHOLERA vaccines ,PREVENTION of cholera ,CHOLERA ,CLINICAL trials ,DISEASE risk factors ,CLUSTER analysis (Statistics) ,COMPARATIVE studies ,GRAM-negative bacteria ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,EVALUATION research ,RANDOMIZED controlled trials ,RELATIVE medical risk ,DISEASE incidence - Abstract
Introduction: Vaccinating a buffer of individuals around a case (ring vaccination) has the potential to target those who are at highest risk of infection, reducing the number of doses needed to control a disease. We explored the potential vaccine effectiveness (VE) of oral cholera vaccines (OCVs) for such a strategy.Methods and Findings: This analysis uses existing data from a cluster-randomized clinical trial in which OCV or placebo was given to 71,900 participants in Kolkata, India, from 27 July to 10 September 2006. Cholera surveillance was then conducted on 144,106 individuals living in the study area, including trial participants, for 5 y following vaccination. First, we explored the risk of cholera among contacts of cholera patients, and, second, we measured VE among individuals living within 25 m of cholera cases between 8 and 28 d after onset of the index case. For the first analysis, individuals living around each index case identified during the 5-y period were assembled using a ring to define cohorts of individuals exposed to cholera index cases. An index control without cholera was randomly selected for each index case from the same population, matched by age group, and individuals living around each index control were assembled using a ring to define cohorts not exposed to cholera cases. Cholera attack rates among the exposed and non-exposed cohorts were compared using different distances from the index case/control to define the rings and different time frames to define the period at risk. For the VE analysis, the exposed cohorts were further stratified according to the level of vaccine coverage into high and low coverage strata. Overall VE was assessed by comparing the attack rates between high and low vaccine coverage strata irrespective of individuals' vaccination status, and indirect VE was assessed by comparing the attack rates among unvaccinated members between high and low vaccine coverage strata. Cholera risk among the cohort exposed to cholera cases was 5-11 times higher than that among the cohort not exposed to cholera cases. The risk gradually diminished with an increase in distance and time. The overall and indirect VE measured between 8 and 28 d after exposure to a cholera index case during the first 2 y was 91% (95% CI 62%-98%) and 93% (95% CI 44%-99%), respectively. VE persisted for 5 y after vaccination and was similar whether the index case was a young child (<5 y) or was older. Of note, this study was a reanalysis of a cholera vaccine trial that used two doses; thus, a limitation of the study relates to the assumption that a single dose, if administered quickly, will induce a similar level of total and indirect protection over the short term as did two doses.Conclusions: These findings suggest that high-level protection can be achieved if individuals living close to cholera cases are living in a high coverage ring. Since this was an observational study including participants who had received two doses of vaccine (or placebo) in the clinical trial, further studies are needed to determine whether a ring vaccination strategy, in which vaccine is given quickly to those living close to a case, is feasible and effective.Trial Registration: ClinicalTrials.gov NCT00289224. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
32. Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
- Author
-
Horton, Katherine C., MacPherson, Peter, Houben, Rein M. G. J., White, Richard G., and Corbett, Elizabeth L.
- Subjects
GENDER differences (Psychology) ,TUBERCULOSIS diagnosis ,GENDER specific care ,DIAGNOSTIC services ,MIDDLE-income countries ,LOW-income countries - Abstract
Background: Tuberculosis (TB) case notification rates are usually higher in men than in women, but notification data are insufficient to measure sex differences in disease burden. This review set out to systematically investigate whether sex ratios in case notifications reflect differences in disease prevalence and to identify gaps in access to and/or utilisation of diagnostic services.Methods and Findings: In accordance with the published protocol (CRD42015022163), TB prevalence surveys in nationally representative and sub-national adult populations (age ≥ 15 y) in low- and middle-income countries published between 1 January 1993 and 15 March 2016 were identified through searches of PubMed, Embase, Global Health, and the Cochrane Database of Systematic Reviews; review of abstracts; and correspondence with the World Health Organization. Random-effects meta-analyses examined male-to-female (M:F) ratios in TB prevalence and prevalence-to-notification (P:N) ratios for smear-positive TB. Meta-regression was done to identify factors associated with higher M:F ratios in prevalence and higher P:N ratios. Eighty-three publications describing 88 surveys with over 3.1 million participants in 28 countries were identified (36 surveys in Africa, three in the Americas, four in the Eastern Mediterranean, 28 in South-East Asia and 17 in the Western Pacific). Fifty-six surveys reported in 53 publications were included in quantitative analyses. Overall random-effects weighted M:F prevalence ratios were 2.21 (95% CI 1.92-2.54; 56 surveys) for bacteriologically positive TB and 2.51 (95% CI 2.07-3.04; 40 surveys) for smear-positive TB. M:F prevalence ratios were highest in South-East Asia and in surveys that did not require self-report of signs/symptoms in initial screening procedures. The summary random-effects weighted M:F ratio for P:N ratios was 1.55 (95% CI 1.25-1.91; 34 surveys). We intended to stratify the analyses by age, HIV status, and rural or urban setting; however, few studies reported such data.Conclusions: TB prevalence is significantly higher among men than women in low- and middle-income countries, with strong evidence that men are disadvantaged in seeking and/or accessing TB care in many settings. Global strategies and national TB programmes should recognise men as an underserved high-risk group and improve men's access to diagnostic and screening services to reduce the overall burden of TB more effectively and ensure gender equity in TB care. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
33. Accelerating the Uptake and Timing of Antiretroviral Therapy Initiation in Sub-Saharan Africa: An Operations Research Agenda.
- Author
-
Rosen, Sydney, Fox, Matthew P., Larson, Bruce A., Sow, Papa Salif, Ehrenkranz, Peter D., Venter, Francois, Manabe, Yukari C., Kaplan, Jonathan, null, null, and Models for Accelerating Treatment Initiation (MATI) Technical Consultation
- Subjects
AIDS prevention ,MEDICAL care of HIV-positive persons ,HIV antibodies ,ANTIRETROVIRAL agents ,INTERNATIONAL cooperation - Abstract
Sydney Rosen and colleagues describe an operations research agenda to accelerating uptake of HIV treatment initiation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
34. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial.
- Author
-
Rosen, Sydney, Maskew, Mhairi, Fox, Matthew P., Nyoni, Cynthia, Mongwenyana, Constance, Malete, Given, Sanne, Ian, Bokaba, Dorah, Sauls, Celeste, Rohr, Julia, and Long, Lawrence
- Subjects
ANTIRETROVIRAL agents ,DIAGNOSIS of HIV infections ,CD4 antigen ,TUBERCULOSIS treatment ,HIGHLY active antiretroviral therapy ,RANDOMIZED controlled trials ,THERAPEUTICS ,ANTI-HIV agents ,OUTPATIENT medical care ,COMPARATIVE studies ,HOSPITALS ,RESEARCH methodology ,MEDICAL cooperation ,PRIMARY health care ,RESEARCH ,RESEARCH funding ,TIME ,PUBLIC sector ,EVALUATION research ,TREATMENT effectiveness ,CD4 lymphocyte count - Abstract
Background: High rates of patient attrition from care between HIV testing and antiretroviral therapy (ART) initiation have been documented in sub-Saharan Africa, contributing to persistently low CD4 cell counts at treatment initiation. One reason for this is that starting ART in many countries is a lengthy and burdensome process, imposing long waits and multiple clinic visits on patients. We estimated the effect on uptake of ART and viral suppression of an accelerated initiation algorithm that allowed treatment-eligible patients to be dispensed their first supply of antiretroviral medications on the day of their first HIV-related clinic visit.Methods and Findings: RapIT (Rapid Initiation of Treatment) was an unblinded randomized controlled trial of single-visit ART initiation in two public sector clinics in South Africa, a primary health clinic (PHC) and a hospital-based HIV clinic. Adult (≥18 y old), non-pregnant patients receiving a positive HIV test or first treatment-eligible CD4 count were randomized to standard or rapid initiation. Patients in the rapid-initiation arm of the study ("rapid arm") received a point-of-care (POC) CD4 count if needed; those who were ART-eligible received a POC tuberculosis (TB) test if symptomatic, POC blood tests, physical exam, education, counseling, and antiretroviral (ARV) dispensing. Patients in the standard-initiation arm of the study ("standard arm") followed standard clinic procedures (three to five additional clinic visits over 2-4 wk prior to ARV dispensing). Follow up was by record review only. The primary outcome was viral suppression, defined as initiated, retained in care, and suppressed (≤400 copies/ml) within 10 mo of study enrollment. Secondary outcomes included initiation of ART ≤90 d of study enrollment, retention in care, time to ART initiation, patient-level predictors of primary outcomes, prevalence of TB symptoms, and the feasibility and acceptability of the intervention. A survival analysis was conducted comparing attrition from care after ART initiation between the groups among those who initiated within 90 d. Three hundred and seventy-seven patients were enrolled in the study between May 8, 2013 and August 29, 2014 (median CD4 count 210 cells/mm3). In the rapid arm, 119/187 patients (64%) initiated treatment and were virally suppressed at 10 mo, compared to 96/190 (51%) in the standard arm (relative risk [RR] 1.26 [1.05-1.50]). In the rapid arm 182/187 (97%) initiated ART ≤90 d, compared to 136/190 (72%) in the standard arm (RR 1.36, 95% confidence interval [CI], 1.24-1.49). Among 318 patients who did initiate ART within 90 d, the hazard of attrition within the first 10 mo did not differ between the treatment arms (hazard ratio [HR] 1.06; 95% CI 0.61-1.84). The study was limited by the small number of sites and small sample size, and the generalizability of the results to other settings and to non-research conditions is uncertain.Conclusions: Offering single-visit ART initiation to adult patients in South Africa increased uptake of ART by 36% and viral suppression by 26%. This intervention should be considered for adoption in the public sector in Africa.Trial Registration: ClinicalTrials.gov NCT01710397, and South African National Clinical Trials Register DOH-27-0213-4177. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
35. Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions.
- Author
-
Lienhardt, Christian, Lönnroth, Knut, Menzies, Dick, Balasegaram, Manica, Chakaya, Jeremiah, Cobelens, Frank, Cohn, Jennifer, Denkinger, Claudia M., Evans, Thomas G., Källenius, Gunilla, Kaplan, Gilla, Kumar, Ajay M. V., Matthiessen, Line, Mgone, Charles S., Mizrahi, Valerie, Mukadi, Ya-diul, Nguyen, Viet Nhung, Nordström, Anders, Sizemore, Christine F., and Spigelman, Melvin
- Subjects
TUBERCULOSIS treatment ,POINT-of-care testing ,TUBERCULOSIS vaccines ,TUBERCULOSIS prevention ,MEDICAL care of tuberculosis patients ,DRUG therapy for tuberculosis ,ANTITUBERCULAR agents ,BACTERIAL vaccines ,DRUG design ,HEALTH services accessibility ,RESEARCH ,WORLD health ,DISEASE eradication ,VACCINES - Abstract
Christian Lienhardt and colleagues describe the research efforts needed to end the global tuberculosis epidemic by 2035. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
36. Sexually transmitted infections-Research priorities for new challenges.
- Author
-
Low, Nicola and Broutet, Nathalie J.
- Subjects
SEXUALLY transmitted diseases ,MOLECULAR diagnosis ,URETHRITIS ,UTERINE cervicitis ,DIGITAL technology ,PAPILLOMAVIRUS disease prevention ,PREVENTION of sexually transmitted diseases ,DISEASE relapse prevention ,TUMOR prevention ,PREVENTION of communicable diseases ,INTERNAL medicine ,RESEARCH ,CERVIX uteri tumors - Abstract
In an Editorial, Guest Editors Nicola Low and Nathalie Broutet discuss the Collection on sexually transmitted infections in the context of research priorities in the field. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
37. Impact of Xpert MTB/RIF for TB Diagnosis in a Primary Care Clinic with High TB and HIV Prevalence in South Africa: A Pragmatic Randomised Trial.
- Author
-
Cox, Helen S., Mbhele, Slindile, Mohess, Neisha, Whitelaw, Andrew, Muller, Odelia, Zemanay, Widaad, Little, Francesca, Azevedo, Virginia, Simpson, John, Boehme, Catharina C., and Nicol, Mark P.
- Subjects
TUBERCULOSIS diagnosis ,DIAGNOSIS of HIV infections ,PRIMARY care ,DISEASE prevalence ,BACTERIOLOGY - Abstract
: Helen Cox and colleagues investigate the impact Xpert MTB/RIF for diagnosing patients with presumptive tuberculosis in a large primary care clinic in Khayelitsha, Cape Town. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
38. Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial.
- Author
-
Tregnaghi, Miguel W., Sáez-Llorens, Xavier, López, Pio, Abate, Hector, Smith, Enrique, Pósleman, Adriana, Calvo, Arlene, Wong, Digna, Cortes-Barbosa, Carlos, Ceballos, Ana, Tregnaghi, Marcelo, Sierra, Alexandra, Rodriguez, Mirna, Troitiño, Marisol, Carabajal, Carlos, Falaschi, Andrea, Leandro, Ana, Castrejón, Maria Mercedes, Lepetic, Alejandro, and Lommel, Patricia
- Subjects
PNEUMOCOCCAL pneumonia ,PNEUMONIA in children ,CLINICAL trials - Abstract
In a double-blind randomized controlled trial, Xavier Saez-Llorens and colleagues examine the vaccine efficacy of PHiD-CV against community-acquired pneumonia in young children in Panama, Argentina, and Columbia. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
39. Risk of Early-Onset Neonatal Infection with Maternal Infection or Colonization: A Global Systematic Review and Meta-Analysis.
- Author
-
Chan, Grace J., Lee, Anne CC, Baqui, Abdullah H., Tan, Jingwen, and Black, Robert E.
- Subjects
NEONATAL infections ,META-analysis ,ANTIBIOTICS ,SEPSIS ,BACTEREMIA - Abstract
: Grace Chan and coauthors conducted a systematic review and meta-analysis of studies evaluating the risk of neonatal infection or colonization during the first seven days of life among newborns of mothers with bacterial infection or colonization during the intrapartum period. Please see later in the article for the Editors' Summary [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
40. Research on Implementation of Interventions in Tuberculosis Control in Low- and Middle-Income Countries: A Systematic Review
- Author
-
Cobelens, Frank, van Kampen, Sanne, Ochodo, Eleanor, Atun, Rifat, and Lienhardt, Christian
- Subjects
TUBERCULOSIS prevention ,MIDDLE-income countries ,SYSTEMATIC reviews ,RANDOMIZED controlled trials - Abstract
Cobelens and colleagues systematically reviewed research on implementation and cost-effectiveness of the WHO-recommended interventions for tuberculosis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
41. Surveillance of Infection Severity: A Registry Study of Laboratory Diagnosed Clostridium difficile.
- Author
-
Schlackow, Iryna, Sarah Walker, A., Dingle, Kate, Griffiths, David, Oakley, Sarah, Finney, John, Gill, Martin J., Crook, Derrick W., Peto, Tim E. A., and Wyllie, David H.
- Subjects
MICROBIAL virulence ,CLONING ,PATHOGENIC bacteria ,BACTERIAL diseases ,CLOSTRIDIOIDES difficile - Abstract
Background: Changing clinical impact, as virulent clones replace less virulent ones, is a feature of many pathogenic bacterial species and can be difficult to detect. Consequently, innovative techniques monitoring infection severity are of potential clinical value. Methods and Findings: We studied 5,551 toxin-positive and 20,098 persistently toxin-negative patients tested for Clostridium difficile infection between February 1998 and July 2009 in a group of hospitals based in Oxford, UK, and investigated 28-day mortality and biomarkers of inflammation (blood neutrophil count, urea, and creatinine concentrations) collected at diagnosis using iterative sequential regression (ISR), a novel joinpoint-based regression technique suitable for serial monitoring of continuous or dichotomous outcomes. Among C. difficile toxin-positive patients in the Oxford hospitals, mean neutrophil counts on diagnosis increased from 2003, peaked in 2006-2007, and then declined; 28-day mortality increased from early 2006, peaked in late 2006-2007, and then declined. Molecular typing confirmed these changes were likely due to the ingress of the globally distributed severe C. difficile strain, ST1. We assessed the generalizability of ISR-based severity monitoring in three ways. First, we assessed and found strong (p<0.0001) associations between isolation of the ST1 severe strain and higher neutrophil counts at diagnosis in two unrelated large multi-centre studies, suggesting the technique described might be useful elsewhere. Second, we assessed and found similar trends in a second group of hospitals in Birmingham, UK, from which 5,399 cases were analysed. Third, we used simulation to assess the performance of this surveillance system given the ingress of future severe strains under a variety of assumptions. ISR-based severity monitoring allowed the detection of the severity change years earlier than mortality monitoring. Conclusions: Automated electronic systems providing early warning of the changing severity of infectious conditions can be established using routinely collected laboratory hospital data. In the settings studied here these systems have higher performance than those monitoring mortality, at least in C. difficile infection. Such systems could have wider applicability for monitoring infections presenting in hospital. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
42. Editors' Summary.
- Subjects
- *
TUBERCULOSIS , *MYCOBACTERIAL diseases , *BACTERIAL diseases , *MEDICAL personnel , *COMMUNICABLE diseases - Abstract
The article presents an editors' summary of the paper "Rates of Latent Tuberculosis in Health Care Staff in Russia." The editors note that tuberculosis is a very common and life-threatening infection caused by Mycobacterium tuberculosis. Many people who are infected do not develop the symptoms of disease. This is called latent infection. Reasons why this study was made, what did the researchers do and find, and the significance of the findings are provided.
- Published
- 2007
43. Association of Secondhand Smoke Exposure with Pediatric Invasive Bacterial Disease and Bacterial Carriage: A Systematic Review and Meta-analysis.
- Author
-
Chien-Chang Lee, Middaugh, Nicole A., Howie, Stephen R. C., and Ezzati, Majid
- Subjects
EPIDEMIOLOGICAL research ,HEALTH ,SMOKING ,PHYSIOLOGICAL effects of smoke ,BACTERIAL diseases ,META-analysis ,SYSTEMATIC reviews ,NEISSERIA meningitidis ,HAEMOPHILUS influenzae - Abstract
Background: A number of epidemiologic studies have observed an association between secondhand smoke (SHS) exposure and pediatric invasive bacterial disease (IBD) but the evidence has not been systematically reviewed. We carried out a systematic review and meta-analysis of SHS exposure and two outcomes, IBD and pharyngeal carriage of bacteria, for Neisseria meningitidis (N. meningitidis), Haemophilus influenzae type B (Hib), and Streptococcus pneumoniae (S. pneumoniae). Methods and Findings: Two independent reviewers searched Medline, EMBASE, and selected other databases, and screened articles for inclusion and exclusion criteria. We identified 30 case-control studies on SHS and IBD, and 12 crosssectional studies on SHS and bacterial carriage. Weighted summary odd ratios (ORs) were calculated for each outcome and for studies with specific design and quality characteristics. Tests for heterogeneity and publication bias were performed. Compared with those unexposed to SHS, summary OR for SHS exposure was 2.02 (95% confidence interval [CI] 1.52-2.69) for invasive meningococcal disease, 1.21 (95% CI 0.69-2.14) for invasive pneumococcal disease, and 1.22 (95% CI 0.93-1.62) for invasive Hib disease. For pharyngeal carriage, summary OR was 1.68 (95% CI, 1.19-2.36) for N. meningitidis, 1.66 (95% CI 1.33-2.07) for S. pneumoniae, and 0.96 (95% CI 0.48-1.95) for Hib. The association between SHS exposure and invasive meningococcal and Hib diseases was consistent regardless of outcome definitions, age groups, study designs, and publication year. The effect estimates were larger in studies among children younger than 6 years of age for all three IBDs, and in studies with the more rigorous laboratory-confirmed diagnosis for invasive meningococcal disease (summary OR 3.24; 95% CI 1.72-6.13). Conclusions: When considered together with evidence from direct smoking and biological mechanisms, our systematic review and meta-analysis indicates that SHS exposure may be associated with invasive meningococcal disease. The epidemiologic evidence is currently insufficient to show an association between SHS and invasive Hib disease or pneumococcal disease. Because the burden of IBD is highest in developing countries where SHS is increasing, there is a need for high-quality studies to confirm these results, and for interventions to reduce exposure of children to SHS. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
44. Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations.
- Author
-
Ariza, Javier, Bosilkovski, Mile, Cascio, Antonio, Colmenero, Juan D., Corbel, Michael J., Falagas, Matthew E., Memish, Ziad A., Hasanjani Roushan, Mohammad Reza, Rubinstein, Ethan, Sipsas, Nikolaos V., Solera, Javier, Young, Edward J., and Pappas, Georgios
- Subjects
BRUCELLOSIS ,CLINICAL trials ,GRAM-negative bacterial diseases ,THERAPEUTICS ,BACTERIAL diseases - Abstract
The authors provide evidence-based guidance on treating human brucellosis, and discuss the future clinical trials that would help address the controversies surrounding treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
45. Tuberculosis among Health-Care Workers in Low- and Middle-Income Countries: A Systematic Review.
- Author
-
Joshi, Rajnish, Reingold, Arthur L., Menzies, Dick, and Pai, Madhukar
- Subjects
MYCOBACTERIUM tuberculosis ,INFECTIOUS disease transmission ,BACTERIAL diseases ,TUBERCULOSIS risk factors ,PATIENT-professional relations ,HEALTH facilities - Abstract
Background The risk of transmission of Mycobacterium tuberculosis from patients to health-care workers (HCWs) is a neglected problem in many low- and middle-income countries (LMICs). Most health-care facilities in these countries lack resources to prevent nosocomial transmission of tuberculosis (TB). Methods and Findings We conducted a systematic review to summarize the evidence on the incidence and prevalence of latent TB infection (LTBI) and disease among HCWs in LMICs, and to evaluate the impact of various preventive strategies that have been attempted. To identify relevant studies, we searched electronic databases and journals, and contacted experts in the field. We identified 42 articles, consisting of 51 studies, and extracted data on incidence, prevalence, and risk factors for LTBI and disease among HCWs. The prevalence of LTBI among HCWs was, on average, 54% (range 33% to 79%). Estimates of the annual risk of LTBI ranged from 0.5% to 14.3%, and the annual incidence of TB disease in HCWs ranged from 69 to 5,780 per 100,000. The attributable risk for TB disease in HCWs, compared to the risk in the general population, ranged from 25 to 5,361 per 100,000 per year. A higher risk of acquiring TB disease was associated with certain work locations (inpatient TB facility, laboratory, internal medicine, and emergency facilities) and occupational categories (radiology technicians, patient attendants, nurses, ward attendants, paramedics, and clinical officers). Conclusions In summary, our review demonstrates that TB is a significant occupational problem among HCWs in LMICs. Available evidence reinforces the need to design and implement simple, effective, and affordable TB infection-control programs in health-care facilities in these countries. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
46. Adherence clubs and decentralized medication delivery to support patient retention and sustained viral suppression in care: Results from a cluster-randomized evaluation of differentiated ART delivery models in South Africa
- Author
-
Sydney Rosen, Mokgadi Phokojoe, David Wilson, Sophie Js Pascoe, Nicole Fraser-Hurt, Joshua Murphy, Marelize Gorgens, Matthew P. Fox, Yogan Pillay, and Amy N Huber
- Subjects
Male ,RNA viruses ,Bacterial Diseases ,Health Knowledge, Attitudes, Practice ,Time Factors ,Sustained Virologic Response ,Psychological intervention ,HIV Infections ,030204 cardiovascular system & hematology ,Pathology and Laboratory Medicine ,Health Services Accessibility ,Geographical locations ,law.invention ,South Africa ,0302 clinical medicine ,Immunodeficiency Viruses ,Randomized controlled trial ,law ,Retention in Care ,Medicine and Health Sciences ,Public and Occupational Health ,Peer Influence ,030212 general & internal medicine ,Young adult ,Pharmaceutics ,General Medicine ,Middle Aged ,Viral Load ,Vaccination and Immunization ,3. Good health ,Treatment Outcome ,Infectious Diseases ,Medical Microbiology ,Research Design ,Viral Pathogens ,Viruses ,Observational Studies ,Tuberculosis Diagnosis and Management ,Medicine ,Female ,Pathogens ,Fast track ,Viral load ,Research Article ,Adult ,medicine.medical_specialty ,Patient Dropouts ,Randomization ,Adolescent ,Anti-HIV Agents ,Immunology ,Antiretroviral Therapy ,Research and Analysis Methods ,Microbiology ,Medication Adherence ,Young Adult ,03 medical and health sciences ,Pharmacotherapy ,Antiviral Therapy ,Drug Therapy ,Diagnostic Medicine ,Virology ,Internal medicine ,Retroviruses ,medicine ,Humans ,Tuberculosis ,Microbial Pathogens ,business.industry ,Lentivirus ,Organisms ,Biology and Life Sciences ,HIV ,Tropical Diseases ,Clinical trial ,Africa ,Preventive Medicine ,People and places ,business ,Viral Transmission and Infection - Abstract
Background Differentiated antiretroviral therapy (ART) delivery models, in which patients are provided with care relevant to their current status (e.g., newly initiating, stable on treatment, or unstable on treatment) has become an essential part of patient-centered health systems. In 2015, the South African government implemented Chronic Disease Adherence Guidelines (AGLs), which involved five interventions: Fast Track Initiation Counseling for newly initiating patients, Enhanced Adherence Counseling for patients with an unsuppressed viral load, Early Tracing of patients who miss visits, and Adherence Clubs (ACs) and Decentralized Medication Delivery (DMD) for stable patients. We evaluated two of these interventions in 24 South African facilities: ACs, in which patients meet in groups outside usual clinic procedures and receive medication; and DMD, in which patients pick up their medication outside usual pharmacy queues. Methods and findings We compared those participating in ACs or receiving DMD at intervention sites to those eligible for ACs or DMD at control sites. Outcomes were retention and sustained viral suppression (, Matthew Fox and colleagues report on outcomes of two tailored service delivery models for HIV therapy in South Africa., Author summary Why was this study done? Antiretroviral therapy (ART) has brought enormous benefits, enabling HIV patients to live longer and healthier lives. However, many patients struggle to adhere to this lifelong treatment, and their retention in care is suboptimal. To address this, South Africa’s National Department of Health has introduced National Adherence Guidelines for Chronic Diseases that recommend key interventions suitable for new patients, clinically stable patients, patients with advanced HIV disease or on a failing ART regimen, and lost-to-follow-up patients. The early implementation of these guidelines from 2015 was evaluated to understand the effectiveness of five interventions and learn about improvements for the guidelines’ rollout. This paper provides the results on adherence clubs and decentralized medication delivery, two interventions for efficient medication pick-up by clinically stable patients. What did the researchers do and find? We used a cluster-randomized evaluation design for adherence clubs and an observational study for decentralized medication delivery across 12 intervention and 12 control health facilities in 4 provinces. The 275 adherence club patients had improved retention in care at one year compared to the 294 controls, especially men, and comparable viral suppression within 18 months. The 232 patients receiving decentralized medication delivery had apparently lower retention in care than the 346 controls (possibly due to medication pick-up data not reaching clinics), and viral suppression was comparable overall, but men on decentralized medication delivery had apparently increased viral suppression. What do these findings mean? This programmatic evaluation with a comparison group provides the National Department of Health with many lessons for the national rollout of the guidelines and the effect one can expect from such alternative medication pick-up services. The control facilities were already offering some adherence and retention services, and the observed benefits of the guideline interventions are therefore additional. The comparable outcomes for decentralized medication delivery against standard of care, the retention benefit by adherence clubs, and the apparent increased effects among men suggest that these interventions can play an important role in South Africa’s ART program. Because the interventions also decentralize ART and reduce patients’ inconvenience, comparable outcomes are a potential success, and further work should investigate the cost–benefit relation and possible effects on decongesting clinics.
- Published
- 2019
47. What Research Is Needed to Stop TB? Introducing the TB Research Movement
- Author
-
Marcos A. Espinal, Dermot Maher, Madhukar Pai, Christian Lienhardt, and Mario C. Raviglione
- Subjects
Bacterial Diseases ,Economic growth ,Tuberculosis ,Biomedical Research ,Pulmonology ,Science Policy ,International Cooperation ,Population ,Global Health ,Research Funding ,Research Support as Topic ,medicine ,Humans ,education ,Health policy ,Strategic planning ,education.field_of_study ,Policy Forum ,business.industry ,Health Policy ,Health services research ,Extensively drug-resistant tuberculosis ,General Medicine ,Research Assessment ,medicine.disease ,Systematic review ,Infectious Diseases ,General partnership ,Respiratory Infections ,Communicable Disease Control ,Medicine ,business - Abstract
With 9.4 million new cases and 1.7 million deaths worldwide in 2009, tuberculosis (TB) constitutes an unacceptable burden of human suffering and loss [1]. The tools available for TB control are old, lack effectiveness, and are not readily accessible in many settings: the diagnosis of pulmonary TB still relies in most high-burden countries on sputum microscopy, a century old technology; treatment of tuberculosis is based on drugs that are over 40 years old and requires direct supervision to ensure full treatment adherence and prevent drug resistance; and the only TB vaccine (BCG), first used in 1922, has a variable protective efficacy in adults. Novel tools are needed for better TB care and control worldwide [2]. Research has a key role to play in meeting health and development goals. Based on the World Health Organization's (WHO) Stop TB Strategy, the Stop TB Partnership has developed the Global Plan to Stop TB 2011–2015, which lays out the activities to be achieved by 2015 towards elimination of TB (defined as ≤1 TB case per million population per year) by 2050 [3]. The plan sets out a roadmap for halving TB prevalence and deaths globally by 2015, compared with 1990 levels. However, while it is estimated that the incidence rate of TB has been falling globally since 2004, the present rate of decline (less than 1% per year) is insufficient to reach the elimination goal by 2050 [1]. Any realistic prospect of achieving this goal depends both on the better and wider use of existing technologies and the development of revolutionary new technologies for TB control. This would be possible only through an acceleration of research across the continuum, from basic to implementation [4]. Recognizing this, the Stop TB Partnership and the WHO Stop TB Department have launched the TB Research Movement, with the aim of boosting TB research and accelerating progress in TB control towards international targets [5],[6]. We describe here the strategy developed to address the objectives (Box 1) of the Research Movement and the progress made over the last 2 years. Box 1. The TB Research Movement Objectives Objectives of the Research Movement: To provide leadership and advocacy to mobilize increased resources in support of a coherent and comprehensive global TB research agenda to meet the Stop TB goals and targets; and To provide a forum for funders and implementers of TB research to coordinate plans and actions, with the result of ensuring that research needs are addressed, opportunities identified, and gaps filled. The Research Movement Strategic Plan The TB Research Movement is based at the Stop TB Partnership secretariat, housed by the WHO in Geneva, and works in close collaboration with the WHO Stop TB Department and with the Working Groups of the Stop TB Partnership. It operates as an umbrella for research-related issues at the Partnership, and receives advice from the Partnership Coordinating Board and the WHO. The strategy plan developed to address the main objectives of the Research Movement has two major components: (1) the analysis of global TB research funding (aimed at estimating the funding gap); and (2) the development of a global TB research roadmap (representing a consensus on global needs across the TB research spectrum). To this end, the Research Movement has mobilized a broad alliance of stakeholders involved in TB research and development, including scientists involved in basic, applied, and operational research, TB control managers and public health officers, donors and aid agencies, and patients and community representatives. Analysis of Global TB Research Funding Mapping the research funding environment involves answering the questions “who is funding TB research and development (R&D)?”, “what is being funded?”, and “how much is being granted?”. For this, the Research Movement has joined with the Treatment Action Group's (TAG) efforts in evaluating the global landscape of funding in TB R&D, through a worldwide survey of funders and donors. This survey has been carried out regularly since 2005 and brings elements of responses to the questions above and helps monitor the trends in funding TB R&D internationally [7] (Figure 1). Figure 1 Investment in TB R&D by research category: 2005–2009 (from TAG report 2010). The revised Global Plan to Stop TB 2011–2015 estimates that at least US$9.8 billion are needed in TB R&D over the next 5 years to reach the targets of 50% reduction in TB prevalence and mortality by 2015, more than twice those estimated in the initial Global Plan to Stop TB 2006–2015 (Table 1) [8]. Importantly, this updated Global Plan includes target investments for fundamental and operationalresearch, on top of the R&D for new drugs, diagnostics, and vaccines. Table 1 Global Plan to Stop TB 2011–2015: total needs (US$ billion). From the above, the research funding gap can be estimated by comparing the results of the R&D funding survey to the research needs outlined in the Global Plan to Stop TB 2011–2015. Based on TAG Report 2010 [7], assuming that 2009 funding estimates are maintained throughout 2011–2015, and adjusting for inflation, the total funding gap for the next 5 years (2011–2015) is estimated at US$6.4 billion (64%) (Figure 2). The biggest gap in absolute terms is in R&D of new drugs, but the largest in relative terms (as a percentage of total funding required for that component) is R&D of new diagnostics. Remarkably, despite a significant boost in funding R&D for new tools in the past few years, TB research globally remains grossly underfunded, with a funding gap that is disproportionately greater for TB research (60%) than for implementation (35%) (Table 2). Figure 2 Funding required and available by research component 2011–2015. Table 2 Funding required and funding available under two possible scenarios and likely funding gaps (US$ billions). The Global TB Research Roadmap In compiling a global TB research agenda, the fundamental question is “what research is required to stop TB?” This involves answering the questions of “what are we researching in TB?” and “are we trying to answer the right questions?”, i.e., “are we doing studies in areas where evidence is lacking?”. In addressing these questions, we needed to identify critical gaps in research that represent bottlenecks for development of new tools. This allowed the development of a coherent and comprehensive global TB research roadmap towards TB elimination that encompasses all aspects of research, from basic science for discovery, to development of new tools, and their optimal uptake for better TB control. The steps in developing the global TB research roadmap include a series of consecutive activities that are described below: (1) an inventory of the research agendas; (2) the development of key research questions; and (3) the prioritization of research questions. Inventory of TB research agendas Over the past decade, a variety of research agendas has been developed by various groups. A systematic review of these TB research agendas was carried out to evaluate the main research questions and themes, assess the methods used to select priorities, and identify any consistent message emerging from these agendas [9]. The review identified 33 papers. The priority areas for research were: drug development (28 articles), diagnosis (27), epidemiology (20), health services research (16), basic research (13), and vaccine development (13) (Table 3). Research questions were usually quite broad in scope. The most focused questions were on treatment and prevention of multidrug-resistant TB and TB/HIV co-infection, reflecting the inefficiencies of sputum-smear microscopy and the limits of the currently recommended short-course chemotherapy, which is inefficient against drug-resistant forms of the disease and is difficult to combine with standard antiretroviral therapy. The importance of epidemiology and health system research probably reflects the need for studies to optimize the availability and cost-effectiveness of interventions for TB control. The relatively low priority assigned to basic research may indicate the difficulty of establishing an agenda in a field that is mostly investigator driven. Table 3 Number of studies identifying priority topics for TB research in a systematic review of 33 articles with TB research priorities. The methods used to identify priorities in these various agendas varied greatly. Most of these relied on expert meetings with consensus seeking, but few used objectively measurable criteria to select research priorities. Increased recourse to systematic reviews and use of clearly described and reproducible criteria to assess the importance of the research questions would greatly help in the establishment of research priorities.
- Published
- 2011
48. A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance
- Author
-
Yehuda Carmeli, Thomas Haustein, Stéphan Juergen Harbarth, John Conly, Ilona Kickbusch, and Didier Wernli
- Subjects
Bacterial Diseases ,Internationality ,Nosocomial Infections ,Epidemiology ,Drug Resistance, Bacterial/drug effects ,Public administration ,Global Health ,Anti-Infective Agents ,Risk Factors ,Global health ,Medicine ,Infection control ,Carbapenems/pharmacology ,health care economics and organizations ,ddc:616 ,Policy Forum ,General Medicine ,humanities ,Klebsiella pneumoniae ,Infectious Diseases ,Population Surveillance ,World Health ,Public Health ,medicine.medical_specialty ,Drugs and Devices ,Infectious Disease Control ,education ,World health ,International Health Regulations ,Infectious Disease Epidemiology ,Adverse Reactions ,Environmental health ,Drug Resistance, Bacterial ,Humans ,ddc:613 ,Public Health/legislation & jurisprudence ,Competing interests ,business.industry ,Public health ,Anti-Infective Agents/pharmacology ,Klebsiella Infections ,Action (philosophy) ,Carbapenems ,Klebsiella pneumoniae/drug effects ,Government Regulation ,Preventive Medicine ,business - Abstract
JC has an unpaid relationship with the World Health Organization in the Department of Global Alert and Response (Infection Prevention and Control Unit). All other authors have declared that no competing interests exist. The authors received no specific funding to write this paper. JC received financial support for a sabbatical leave from the University of Calgary, Calgary, Canada. Provenance: Not commissioned; externally peer reviewed.
- Published
- 2011
49. Viable group A streptococci in macrophages during acute soft tissue infection.
- Author
-
Thulin, Pontus, Johansson, Linda, Low, Donald E., Gan, Bing S., Kotb, Malak, McGeer, Allison, and Norrby-Teglund, Anna
- Subjects
STREPTOCOCCAL diseases ,NECROTIZING fasciitis ,BIOPSY ,MICROBIAL viability counts ,MACROPHAGES ,ANTIBIOTICS ,HOST-parasite relationships ,BACTERIAL diseases ,DRUG therapy ,BACTERIAL proteins ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,MONOCYTES ,PHAGOCYTOSIS ,RESEARCH ,RESEARCH funding ,STREPTOCOCCUS ,TOXINS ,EVALUATION research ,SOFT tissue infections ,PHYSIOLOGY - Abstract
Background: Group A streptococcal severe soft tissue infections, such as necrotizing fasciitis, are rapidly progressive infections associated with high mortality. Group A streptococcus is typically considered an extracellular pathogen, but has been shown to reside intracellularly in host cells.Methods and Findings: We characterized in vivo interactions between group A streptococci (GAS) and cells involved in innate immune responses, using human biopsies (n = 70) collected from 17 patients with soft tissue infections. Immunostaining and in situ image analysis revealed high amounts of bacteria in the biopsies, even in those collected after prolonged antibiotic therapy. Viability of the streptococci was assessed by use of a bacterial viability stain, which demonstrated viable bacteria in 74% of the biopsies. GAS were present both extracellularly and intracellularly within phagocytic cells, primarily within macrophages. Intracellular GAS were predominantly noted in biopsies from newly involved tissue characterized by lower inflammation and bacterial load, whereas purely extracellular GAS or a combination of intra- and extracellular GAS dominated in severely inflamed tissue. The latter tissue was also associated with a significantly increased amount of the cysteine protease streptococcal pyrogenic exotoxin SpeB. In vitro studies confirmed that macrophages serve as reservoirs for viable GAS, and infection with a speB-deletion mutant produced significantly lower frequencies of cells with viable GAS following infection as compared to the wild-type bacteria.Conclusions: This is the first study to demonstrate that GAS survive intracellularly in macrophages during acute invasive infections. This intracellular presence may have evolved as a mechanism to avoid antibiotic eradication, which may explain our finding that high bacterial load is present even in tissue collected after prolonged intravenous antibiotic therapy. This new insight into the pathogenesis of streptococcal soft tissue infections highlights a need for alternative therapeutic strategies. [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.